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ABSTRACT 
 
Abstract 
Macrophage Class A scavenger receptors (SR-A) are trimeric 
transmembrane glycoproteins that can bind a variety of ligands including 
modified lipoproteins and bacterial products.  Through its ability to internalize 
these ligands, SR-A is thought to be involved in many physiological and 
pathophysiological processes such as host defense and atherosclerosis.  In 
vitro, SR-A also mediates cell adhesion to modified extracellular matrix 
proteins. However, the physiological role of SR-A mediated cell adhesion is 
unknown. 
The goal of this project was to dissect SR-A mediated cell adhesion 
and ligand internalization through structure-function studies and to develop a 
mutant of SR-A that specifically lacks the adhesive properties.  
It appeared that SR-A mediated adhesion and ligand internalization 
depend on the same extracellular domain.  Therefore, I investigated the role 
of cytoplasmic domains for SR-A mediated adhesion.  Different cytoplasmic 
mutated SR-A constructs were stably expressed in human embryonic kidney 
(HEK 293) cells.  I found that a mutated SR-A deficient in all but the six amino 
acids proximal to the membrane of the cytoplasmic tail (SR-A1-49) was able to 
mediate cell adhesion, but not receptor internalization.  Substitution of the SR-
A cytoplasmic tail with that of the transferrin receptor resulted in retention of 
this chimeric receptor in the endoplasmic reticulum demonstrating that the 
SR-A membrane proximal amino acids are also critical for transport of the 
receptor from the endoplasmic reticulum to the Golgi apparatus.  
 In summary, my results demonstrate that SR-A-mediated adhesion and 
internalization require distinct cytoplasmic domains and I developed a mutant 
SR-A (SR-A1-49) that specifically meditates cell adhesion. This mutant will 
make it possible to specifically address the physiological role of SR-A 
mediated adhesion. 
ABSTRAKT 
 
Abstrakt 
Die Makrophagen Scavenger-Rezeptoren der Klasse A (SR-A) sind 
trimere integrale Transmembranproteine, die eine Vielfalt von Liganden (z.B. 
modifizierte Lipoproteine und bakterielle Produkte) binden. Durch 
Internalisation dieser Liganden spielt SR-A eine wichtige Rolle in 
verschiedenen physiologischen und pathophysiologischen Vorgängen, unter 
anderem im Abwehrsystem und bei der Pathogenese der Arteriosklerose. In 
vitro kann SR-A auch die Adhäsion von Makrophagen zu modifizierten 
extrazellulären Matrixproteinen regulieren, die physiologische Bedeutung 
dieser Adhäsionseigenschaften ist allerdings noch unklar.  
Das Ziel dieser Arbeit war es, die Adhäsionseigenschaften von den 
Internalisationeigenschaften des Rezeptors zu trennen und einen mutierten 
SR-A zu entwickeln, dem die Adhäsionseingenschaften fehlen.  
Da Zelladhäsion und Internalisation von Liganden anscheinend von 
einer identischen extrazellulären Region des Rezeptors reguliert werden, 
habe ich die zytoplasmatische Region des Rezeptors erforscht.  Veschiedene 
mutierte SR-A Konstrukte wurden in HEK-293 (human embryonic kidney) 
Zellen exprimiert. Mit diesem Ansatz konnte gezeigt werden, dass ein 
mutierter SR-A (SR-A1-49)  mit einer verkürzten zytoplasmatischen Region 
von nur sechs Aminosäuren Zelladhäsion regulieren kann, aber  nicht in der 
Lage ist, die Internalisation des Rezeptors zu regulieren. Studien mit einem 
chimären Rezeptor, in den der zytoplasmatische Teil von SR-A durch den des 
Transferrin Rezeptors ersetzt wurde, haben gezeigt, dass diese 
zytoplasmatische SR-A Region auch für den Transport vom 
Endoplasmatischen Reticulum zum Golgi Apparat nötig ist.  
Es konnte gezeigt werden, dass Zelladhäsion und Internalisation von 
unterschiedlichen zytoplasmatischen Regionen reguliert werden. Es wurde ein 
mutierter SR-A entwickelt, der spezifisch die Zelladhäsion reguliert und 
anhand dieses Rezeptors kann die physiologische Bedeutung der 
Adhäsionseigenschaften untersucht werden.  
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Abbreviations 
 
aa   amino acid(s) 
AcLDL  acetylated low-density lipoprotein 
ApoE   apolipoprotein E 
bp   base pairs 
BSA   bovine serum albumin 
C-   carboxy- 
d   density [g/ml] 
DMEM  Dulbecco's modified Eagle's medium 
EDTA   Ethylenediaminetetraacetic acid 
E. coli   Escherichia coli 
EndoH  endoglycosidase H 
ER   endoplasmic reticulum 
FBS   fetal bovine serum 
HEK   human embryonic kidney 
kDa   kilodalton 
LDL   low-density lipoprotein 
LDL-R   low-density lipoprotein receptor 
N-   amino- 
OD   optical density 
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
RT   reverse transcriptase 
SDS   sodium dodecyl sulfate 
SR-A   Class A scavenger receptor 
TfR   transferrin receptor 
TfR/SR-A  chimeric transferrin receptor class A scavenger receptor 
u   unit 
v   volume 
w   weight 
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INTRODUCTION 1 
I Introduction 
1. Scavenger Receptors 
Scavenger receptors are defined by their ability to recognize modified low-
density lipoprotein (LDL).  Although scavenger receptors are defined by this 
common function, scavenger receptors have heterogeneous molecular 
structures.  Based on their structure, scavenger receptors are classified in an 
alphabetic scheme from A - G.  The first class includes class A scavenger 
receptors (SR-A) and the structurally similar receptor MARCO (Figure 1).  SR-
A was the first member of the scavenger receptor family to be identified. In 
contrast to the receptor for native LDL, SR-A is not downregulated by 
intracellular cholesterol accumulation.  Therefore, SR-A has been implicated 
in intracellular lipid accumulation during atherosclerosis.  Meanwhile, a broad 
spectrum of ligands has been identified, and SR-A is thought to be involved in 
many physiological and pathophysiological processes.  
 
Type I Type II Type III MARCO
Scavenger Receptor Class A
Cysteine-rich
Collagen-like
-Helical 
Coiled-Coil
Spacer
Transmembrane
Cytoplasmic Cytoplasmic
Transmembrane
Spacer
Collagen-like
Cysteine-rich
-helical coiled-coil
 
 
Figure 1:  Proposed structures of the members of class A of scavenger 
receptors. 
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2. SR-A Structure 
SR-A is a trimeric transmembrane glycoprotein consisting of six distinct 
domains:  an N-terminal cytoplasmic, a transmembrane, and an extracellular 
part composed of short spacer, α-helical coiled-coil, collagen-like, and a 
varying C-terminal domain (Figure 1) (Kodama et al. 1990). Three different 
isoforms of SR-A exist, and these isoforms vary only in their C-terminal 
domain (Freeman et al. 1990; Naito et al. 1992; Ashkenas et al. 1993; Gough 
et al. 1998). The amino acids comprising the different domains of SR-A type I 
are shown in Figure 2. Each trimeric receptor consists of a Cys83 disulfide-
linked dimer and a noncovalently associated monomer (Penman et al. 1991).   
 
 
 
Figure 2:  Structure of murine SR-A type I.  The domains are indicated with 
the corresponding amino acid residues. The number of amino acids 
comprising the domains is shown in brackets.   
Cytoplasmic 1-55 (55 aa)
Transmembrane 56-81 (26 aa)
Collagen-like 277-348   (72 aa)
Cysteine-rich 349 - 458  (110 aa)
-helical coiled-coil   114-276 (163 aa) 
Spacer 82-113  (32 aa)
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SR-A cDNAs have been cloned from bovine liver (Rohrer et al. 1990; Kodama 
et al. 1990), murine macrophage cell line P338D1 (Freeman et al. 1990), 
human monocytic THP-1 cells (Matsumoto et al. 1990) and rabbit smooth 
muscle cells (Bickel et al. 1992; Doi et al. 1993). With a homology between 60 
- 80 %, SR-A is highly conserved between the species (Ashkenas et al. 1993). 
 
Originally the structure of SR-A was proposed to be a straight stalk. However, 
electron microscopy studies showed that the α-helical coiled coil and 
collagen-like domains are connected by an extremely flexible hinge allowing a 
variable angle from 0 to 180 degrees between these two domains. Under 
physiological conditions the predominant angle was 0 degree resulting in 
juxtaposition of the two domains (Figure 3) (Resnick et al. 1996).  
 
 
 
 
 
 
 
 
 
 
Figure 3:   Proposed conformation of SR-A at physiological pH. 
 
2.1. Cytoplasmic domain 
(50 aa human, bovine and rabbit; 55 aa mouse) The cytoplasmic tail has been 
shown to play an important role in regulating SR-A function. A VXFD motif has 
been described to be essential for clathrin coated-pit-mediated endocytosis 
and also for the trafficking of the receptors to the cell surface (Morimoto et al. 
1999). Furthermore, receptor phosphorylation has been shown to regulate cell 
surface expression as well as ligand internalization. The cytoplasmic tail 
contains 3 conserved phosphorylation sites that are conserved among the 
species: Ser21, Thr30
 
and Ser49. The mouse receptor has an additional site at 
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Ser36. Fong et al. described serine, but no threonine phosphorylation during 
internalization of AcLDL (Fong et al. 1999). These investigators performed 
site-directed mutatgenesis replacing Ser21 and Ser49 with alanine to eliminate 
the phosphorylation sites. Elimination of Ser21 increased cell surface 
expression and uptake of AcLDL. Elimination of Ser49 did not affect cell 
surface expression, but slowed receptor internalization (Fong et al. 1999). In 
contrast, other investigators showed that mimicking phosphorylation by 
substitution of Ser49 with aspartate resulted into strongly reduced cell surface 
expression (Heider et al. 2001). Although the studies on the role of 
phosphorylation appear to be inconsistent, they support an important role for 
the cytoplasmic tail in receptor regulation.  
 
2.2. Transmembrane domain 
(26 aa) This transmembrane domain is a stretch of hydrophobic amino acids 
that anchors the receptor in the membrane.  
2.3. Spacer domain 
(32 aa) The spacer domain contains the cysteine residues (cys83) involved in 
formation of the dimer, which noncovalently associates with a monomer to 
form the trimeric receptor. However, the disulfide-linked dimer formation was 
not required for trimer formation and SR-A function (Penman et al. 1991). 
2.4. α-helical coiled-coil domain 
 (163 aa) This domain consists of 23 seven amino acid “heptads” repeats (a-
b-c-d-e-f)n. The first (a) and fourth (d) amino acids of these repeats have 
hydrophobic aliphatic side chains (leucine, isoleucine and valine), which form 
an interhelical hydrophobic core holding together the trimeric helix (Doi et al. 
1993). Doi et al. have demonstrated that the -helical coiled-coil is essential  
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for trimer formation  expressing truncated forms of the scavenger receptor 
and analyzing timer formation (Doi et al. 1993). 
 
A discontinuity of the heptad repeats has been identified at Asn203 and it has 
been proposed that the -helical coiled-coil is divided into two functional 
subdomains (Suzuki et al. 1997). The N-terminal half of the domain is 
essential for stable trimer formation and a specific seven-residue sequence 
appears to be required (Suzuki et al. 1997; Frank et al. 2000). The C-terminal 
end determines pH dependent conformational changes (Suzuki et al. 1997). 
The conformation of this domain is a -helical coiled-coil structure at pH 5, 
whereas the structure is random at pH 7 (Suzuki et al. 1997).  Specifically, a 
buried glutamate (Glu242) in this domain is thought to induce this pH-
dependent conformational change (Suzuki et al. 1999). Furthermore, the pH 
dependent ligand dissociation depends on residue His260 within c-terminal end 
of the α-helical coiled-coil (Doi et al. 1994). Substitution of His260 sustained 
ligand binding, but abolished the ability to release the ligands in the lysosome, 
suggesting that this residue allosterically controls the pH dependent ligand 
release from the collagen-like domain (Doi et al. 1994).  
 
A polymorphism of the murine sequence has been described at residue 
Leu168 and led to the identification of the binding site of the most commonly 
used antibody against murine SR-A, 2F8 (Fortin et al. 2000; Daugherty et al. 
2000). 
2.5. Collagen-like domain 
(69 aa human; 72aa bovine, rabbit, mouse) The collagen-like domain has 23 
(human) or 24 (bovine, rabbit, mouse) Gly-x-y tripeptide repeats that 
assemble into a collagenous triple helix. The amino acids in position y are 
mostly prolines or lysines that can be hydroxylated.  The C-terminal 22 amino 
acids are highly conserved and contain a lysine cluster that forms a positively 
charged groove, which specifically interacts with the negatively charged 
ligands (Doi et al. 1993). 
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Truncated mutants lacking the conserved lysine cluster are unable to bind 
modified lipoproteins (Acton et al. 1993; Doi et al. 1993). Point mutations 
studies that substituted the conserved lysines against alanine, demonstrated 
that substitution of lys337 abolishes acLDL degradation and an additional 
substitution (either lys334 or lys340) also abolishes oxLDL degradation (Doi et 
al. 1993). 
 
Studies using synthetic SR-A peptides that contain the ligand binding domain 
(Gly323 to Lys340) have shown that the trimeric structure is necessary for ligand 
binding. While the cross-linked trimeric form of the peptide can bind AcLDL, 
the single stranded peptide cannot (Tanaka et al. 1993; Tanaka et al. 1996). 
Using the same model peptide, it was demonstrated that not only the ligand 
binding, but also the ligand specificity is mediated by the lysine cluster, as the 
trimeric peptide has a ligand binding specificity similar to that of the natural 
receptor (Yamamoto et al. 1997). 
 
2.6. Cysteine-rich domain 
The carboxy-terminal domain varies between the three isoforms of SR-A. The 
carboxy-terminal domain of SR-A type I consists of 110 amino acids 
containing 6 cysteine residues (Kodama et al. 1990) and is referred to as 
cysteine-rich domain. The function of the cysteine-rich domain has not been 
defined yet. However, the identification of this domain lead to the identification 
of family of proteins characterized by scavenger receptor cysteine-rich 
(SRCR) domains (Freeman et al. 1990). 
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3. SR-A isoforms 
The SR-A gene consists of 11 exons (Emi et al. 1993), and three SR-A 
isoforms are generated through alternative splicing of the mRNA (Freeman et 
al. 1990). Exons 2 - 8 are common to all isoforms. In addition, SR-A type I 
contains exons 10 and 11, SR-A type II contains exon 9, and SR-A type III 
contains exon 11 (Freeman et al. 1990; Gough et al. 1998). 
 
The three isoforms vary only in their C-terminal domains. SR-A type I has a C-
terminal cysteine-rich domain of 110 amino acids containing 6 cysteine 
residues (Kodama et al. 1990). This domain is truncated to six amino acids in 
the SR-A type II isoform (Rohrer et al. 1990) and to 49 amino acids containing 
4 cysteines in the type III isoform (Gough et al. 1998).  
 
Despite the structural differences in the cysteine-rich domain, SR-A type I and 
II have the same ligand specificity and affinity (Rohrer et al. 1990; Freeman et 
al. 1991) and the importance of the different isoforms remains unclear. SR-A 
type II has been reported to be the predominant isoform expressed in cultured 
murine macrophages, including P388D1 and RAW264 cells (Ashkenas et al. 
1993). In contrast to SR-A I and II, SR-A type III does not mediate ligand 
internalization. Studies in CHO cells expressing SR-A type III have shown that 
the intracellular processing of this isoform is different from that of SR-A type I 
and II and therefore SR-A III does not localize to the cell surface. 
Furthermore, when coexpressed with type I or type II, SR-A type III functions 
as a dominant negative isoform (Gough et al. 1998). Therefore, SR-A III might 
function as a negative regulator of SR-A type I and II. 
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4. Intracellular processing and trafficking of SR-A 
During synthesis, the monomeric protein chain is inserted into the membrane 
of the ER, whereby the extracellular domains are translocated into the ER 
lumen.  In the ER lumen, the protein is N-linked glycosylated (Asn-X-Ser and 
Asn-X-Thr consensus sequences; 2 in spacer domain and 5 in α-helical coil).  
Furthermore, hydroxylation of prolines and/or lysines of the Gly-x-y repeats in 
the collagen-like domain occurs.  The modified monomers assemble into 
precusor trimers consisting of a Cys83 disulfide-linked dimer and a non-
covalently associated monomer.  These precusor trimers are then transported 
from the ER to the cell surface through the Golgi apparatus, where further 
processing of the N-linked oligosaccharides converts the precusor into the 
endoglycosidase H-resistant mature form (Penman et al. 1991).  An overview 
of the processing of SR-A is shown in Figure 4.  The predicted molecular 
weight of the native monomer based on the amino acid sequence is 50 kDa 
(458 aa mouse) for type I and 38 kDa (354 aa mouse) for type II (Rohrer et al. 
1990; Kodama et al. 1990). The addition of N-linked oligosaccharides results 
in apparent molecular weights of 64/55 kDa for the precursor monomers and 
79/70 kDa for the mature monomers of type I/ type II, respectively (Table 1) 
(Penman et al. 1991).  SR-A type III is processed differently from type I and II 
resulting in retention in the ER (Gough et al. 1998). 
 
kDa 
SR-A native precursor mature 
Type I  50 64 79 
Type  II 38 55 70 
 
Table 1:  Apparent molecular weights (in kDa) of SR-A type I and II at the 
different stages of intracellular processing.  
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Figure 4:  Processing of SR-A.  After translocation of the SR-A 
carboxyterminal extracellular domains into the endoplasmic reticulum (ER), the 
monomeric SR-A is N-linked glycosylated and the glycosylated monomers 
assemble into trimers.  These ‘precursor’ trimers are transported through the 
Golgi apparatus where further processing of the N-linked oligosaccharides 
converts the EndoH-sensitive precursor into the EndoH-resistant mature form 
expressed on the cell surface. The apparent molecular weight of the 
monomeric forms of SR-A type II is indicated. To study the processing of SR-A 
the inhibitors tunicamycin and brefeldin A can be used. Tunicamycin inhibits 
glycosylation of the native protein in the endoplasmic reticulum and brefeldin 
A inhibits maturation of the precursor in the Golgi apparatus.  
 
SR-A localized to the cell surface can mediate internalization of ligands or 
function as an adhesion molecule. SR-A internalizes ligands via clathrin-
coated pit mediated endocytosis (Fukuda et al. 1986). The ligands dissociate 
from the receptor through allosteric changes in the acidic endosomes. The 
released ligands are transported to the lysosome where they are digested; 
while the receptors recycle back to the cell surface (Mori et al. 1994). 
Although it has been proposed that SR-A mediated adhesion results from the 
attempt to internalize an immobilized ligand, the mechanism by which SR-A 
mediates adhesion remains undefined.  
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5. SR-A expression 
5.1. Tissue distribution 
 
SR-A was first identified as receptor for acetylated low-density lipoprotein 
(AcLDL) on macrophages (Goldstein et al. 1979).  While monocytes do not 
express SR-A, several cells of macrophage-lineage have been shown to 
express SR-A including various tissue macrophages in lung, spleen, lymph 
nodes and the specialized liver Kupffer cells and brain microglia cells (Naito et 
al. 1991; Hughes et al. 1995). 
 
Although SR-A is mainly expressed on cells of macrophage-lineage, 
scavenger receptor expression is not limited to those cells. SR-A expression 
has been also detected in liver sinusoidal endothelial cells (Naito et al. 1991), 
aortic endothelial cells (Daugherty et al. 1997), smooth muscle cells and 
fibroblasts (Pitas 1990; Bickel et al. 1992; Mietus-Snyder et al. 2000). 
 
5.2. Regulation of SR-A 
 
Unlike the receptor for native LDL, SR-A is not downregulated by intracellular 
cholesterol accumulation. In contrast, it has been described that SR-A can be 
upregulated by modified lipoproteins such as AcLDL and oxLDL (Yoshida et 
al. 1998; Han et al. 1998).   
 
Several regulators of SR-A expression have been described in cultured cells 
(Table 2).  These regulators include several cytokines that are important 
mediators of inflammatory processes such as interferon- and tumor necrosis 
factor-. However, in many cases contradictory effects have been reported. 
For example interferon- has been reported to upregulate as well as to 
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downregugate SR-A expression. in vivo, the regulation of SR-A is difficult to 
study as the cells are exposed to a complex environment of potential 
regulators.  
 
Upregulation Downregulation 
monocyte/macrophage 
Lymphokines (Kotake et al. 1992) Lymphokines (Fogelman et al. 1982) 
IFN- (Lopes-Virella et al. 1987; Grewal et al. 
1997; Cornicelli et al. 2000) 
IFN- (Geng et al. 1992) 
IL-4 (Cornicelli et al. 2000) IL-6 (Liao et al. 1999) 
IL-1 (Grewal et al. 1997) TGF- (Bottalico et al. 1991; Nishimura et 
al. 1998) 
Phorbol esters (Via et al. 1989) Phorbol esters (Leake et al. 1989; Fong et 
al. 1994) 
Platelet derived products (Phillips et al. 1985) LPS (Van Lenten et al. 1985) 
Dexamethasone (Hirsch et al. 1986) dexamethasone (Moulton et al. 1992) 
M-CSF (de Villiers et al. 1994) TNF- (van Lenten et al. 1992; Hsu et al. 
2000) 
GM-CSF (Cornicelli et al. 2000) GM-CSF (van der Kooij et al. 1996) 
Serum (Fogelman et al. 1981; Pitas 1990) Retionic acids (Horvai et al. 1995) 
cytomegalovirus infection (Guetta et al. 1997) PPAR agonists (Ricote et al. 1998) 
oxLDL (Han et al. 1998)  Protein kinase C inhibitors (Akeson et al. 
1991) 
AcLDL (Han et al. 1998)  -tocopherol (Teupser et al. 1999) 
eicosapentaenoic acid (Saito et al. 1991) essential fatty acid deficiency (Gavino et al. 
1992) 
Smooth muscle cell  
protein kinase c stimulation (Mietus-Snyder et 
al. 1997) 
TGF- (Gong et al. 1995) 
serum (Pitas 1990)  
TNF- (Li et al. 1995)  
IFN- (Li et al. 1995)  
PDGF (Inaba et al. 1992; Gong et al. 1995)  
 
Table 2:  Regulators of SR-A in cultured macrophages and smooth muscle 
cells. 
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6. SR-A Ligands  
SR-A binds a wide array of ligands (Table 3). In addition to modified 
lipoproteins, ligands include proteins, polynucleotides, polysaccharides and 
lipids.  A common feature of SR-A ligands is that they are polyanionic; 
however, not all polyanions are ligands for SR-A. For example, among anionic 
polynucleotides SR-A binds polyinosine and polyguanosine, but not 
polycytidine or polyadenosine.  Another example, among anionic 
polysaccharides, SR-A binds dextran sulfate and fucoidan, but not chondroitin 
sulfate or heparin.  The fact that SR-A can distinguish between structurally 
similar polyanions demonstrates that SR-A selectively recognizes ligands. 
 
Because of the ability to bind a wide array of ligands, SR-A is thought to be 
involved in many physiological and pathophysiological processes.  Through its 
ability to bind modified forms of LDL (Goldstein et al. 1979), SR-A has been 
implicated in atherosclerosis. Furthermore, SR-A has been described to bind 
bacterial wall components such as lipopolysaccharide (LPS) (Hampton et al. 
1991) and lipotechoic acid (Dunne et al. 1994), therefore SR-A is thought to 
play a role in host defense.  By recognizing certain phospholipids such as 
phosphotidylserine (Platt et al. 1998) SR-A is also thought to be involved in 
clearance of apoptotic cells. Recognition of beta-amyloid fibrils (El Khoury et 
al. 1996) and secreted forms of amyloid beta precursor by SR-A (Santiago-
Garcia et al. 2001) has implicated SR-A in Alzheimer's disease.  As SR-A also 
binds advanced glycation end products (AGE) (Araki et al. 1995), SR-A might 
play a role in diabetes. Furthermore, SR-A recognizes several extracelluar 
matrix components that are associated with sites of tissue injury and SR-A 
mediated adhesion to such substrates might enhance macrophage retention.  
Finally, several polysaccharides (fucoidan, carrageenan) and polynucleotides 
(polyinosine and polyguanosine) have been shown to antagonize AcLDL 
binding and a non-peptide synthetic antagonist has been described (Lysko et 
al. 1999). 
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Groups Examples of ligands Possible physiological role 
Modified proteins and 
lipoproteins 
Acetylated LDL 
MDA-LDL 
Copper oxidized LDL 
MDA-albumin 
Atherosclerosis 
Bacterial products Lipopolysaccharides 
Lipoteichoic acid 
Host defense 
Phospholipids Phosphatidylserine Phagocytosis of apoptotic cells 
 beta-amyloid fibrils 
amyloid beta precursor 
Alzheimer's Disease 
Advanced glycation 
end products (AGE) 
AGE-albumin Diabetes 
 Crocodolite asbestos Pulmonary disease 
Polysaccharides Fucoidan 
Carageenan 
Dextran sulphate 
Antagonst 
Polynucleotides Polyinosine 
Polyguanosine 
Antagonist 
synthetic antagonists (E)-methyl 4-chloro-alpha-[4-
(4-chlorophenyl)-1, 5-dihydro-
3-hydroxy-5-oxo-1-(2-
thiazolyl)-2H-pyrrol-2-
ylidene]benzene acetate 
Antagonist 
 
Table 3:  Ligands for SR-A and their possible physiological roles.  
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7. SR-A and disease 
7.1. Atherosclerosis 
The atherosclerotic disease process is characterized by lipid accumulation 
and leukocyte infiltration into the arterial wall, resulting in a chronic 
inflammatory, fibro-proliferative response. Clinical complications related to 
atherosclerosis include embolisms, stroke, and heart attack, which are the 
major causes of disability and death in the Western world (Ross 1993; Ross 
1999). 
 
SR-A has been implicated in atherosclerosis as receptor for modified 
lipoproteins on macrophages (Goldstein et al. 1979). Unlike the receptor for 
native LDL, SR-A is not downregulated by intracellular cholesterol 
accumulation. Therefore, uptake of modified LDL via SR-A might lead to 
unregulated cholesterol accumulation, resulting in the formation of lipid-laden 
macrophages referred to as 'foam cells'. Foam cell formation is one of the 
earliest hallmarks of atherosclerosis and these macrophage-derived foam 
cells are the major cell type in atherosclerotic lesions. Consequently, SR-A 
was thought to promote the development of atherosclerosis via foam cell 
formation.  Supporting a role for SR-A in atherogenesis, immunohistological 
studies have demonstrated the presence of SR-A in atheroslerotic lesions 
(Matsumoto et al. 1990; Yla-Herttuala et al. 1991; Naito et al. 1992; Geng et 
al. 1995; Gough et al. 1999; Nakagawa-Toyama et al. 2001). 
 
As SR-A was thought to mediate foam cell formation, it is generally 
considered to be proatherogenic. With the development of genetically 
modified mouse models it became possible to address the role of SR-A in 
atherogenesis in vivo. Since then, the effects of SR-A deficiency as well as 
SR-A overexpression on atherosclerosis have been studied in several mouse 
models of atherosclerosis (Table 4). 
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Mouse Strain/ 
Background SR-A expression Effect 
SR-A -/- 70% reduction in lesions  (Kamada et al. 2001) 
SR-A -/- 
no difference in serum cholesterol concentration; 
86% in females and 81.5% in males reduction of 
lesions (Babaev et al. 2000) 
C57Bl/6 
No genetic 
manipulation 
 
 
SR-A -/-          
after BMT 
no difference in plasma cholesterol concentrations; 
60% reduction in lesions (Babaev et al. 2000) 
SR-A -/- 46% increase in plasma cholesterol concentrations; 58% decrease in lesion size (Suzuki et al. 1997) 
ApoE -/- YAC SR-A 
transgenic after 
BMT 
20% reduction of serum cholesterol (VLDL+LDL); 
no effect on lesion size (Van Eck et al. 2000) 
SR-A -/- 
18 % and 10 % decrease after 4 wks and 12 wks in 
plasma cholesterol concentrations; 
28% and 23% reduction in lesions (Sakaguchi et al. 
1998) 
SR-A -/-          
after BMT 
no effect on plasma cholesterol concentrations; 
60% (root) and 65% (en face) reduction in lesions 
(Babaev et al. 2000) 
SR-A transgenic 
after BMT 
24% reduction of serum cholesterol (VLDL+LDL) 
74% (root) and 40% (arch) decrease in lesions 
(Whitman et al. 2002) 
LDL receptor -/- 
YAC SR-A 
transgenic      
after BMT  
Increase of total serum choesterol (15-25%); 
no difference in lesion size (Herijgers et al. 2000) 
SR-A -/- 
No effect on serum cholesterol in females, but 50% 
decrease in males. No statistical difference in lesion 
size (tendencies for larger lesions, especially 
female) but changes in cellular characteristics (more 
complex) (de Winther et al. 1999) 
apoE3Leiden 
transgenic 
 
YAC SR-A 
transgenic after 
BMT 
35% reduction in lesion size, Abstract in Circulation 
1999, not published. 
 
Table 4:  In vivo studies addressing the role of SR-A deficiency or 
overexpression in atherosclerosis in mouse models.  The effects on 
plasma/serum cholesterol and atherosclerotic lesion development. YAC: yeast 
artificial chromosome, BMT: bone marrow transplantation. 
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Total SR-A deficiency in C57BL/6 mice, a mouse strain susceptible to diet-
induced atherosclerosis, dramatically decreased lesions development by 
more than 70 % in two independent studies (Babaev et al. 2000; Kamada et 
al. 2001). Total SR-A deficiency was also studied in two C57BL/6 mouse 
strains that are genetically engineered to enhance atherosclerotic lesion 
development: Apolipoprotein E (apoE) and low-density lipoprotein receptor 
(LDL-R) deficient mice.  In apoE deficient mice, SR-A deficiency decreased 
lesion development by 58 % (Suzuki et al. 1997). In LDL-R deficient mice, 
SR-A deficiency decreased lesion development by 23 % (Sakaguchi et al. 
1998). 
 
As SR-A is expressed on macrophages, endothelial cells and smooth muscle 
cells, bone-marrow transplantation studies were performed to specifically 
address the role of SR-A expressed on macrophages, which are derived from 
bone-marrow cells. Transplantation of SR-A deficient bone marrow into SR-A 
wild-type mice on a LDL-R deficient background reduced lesion development 
by 60% (Babaev et al. 2000). 
 
In contrast to the studies on SR-A deficient mice described above which all 
support a pro-atherogenic role of SR-A, studies using SR-A transgenic mice 
support an anti-atherogenic role of SR-A. SR-A overexpression in 
macrophages after bone marrow transfer dramatically decreased lesion 
development in LDL-R deficient mice (Whitman et al. 2002).  Overall, although 
the data are conflicting, the data from these in vivo studies demonstrates the 
importance of SR-A in atherosclerosis.  
 
7.2. Host defense  
SR-A is expressed mainly on macrophages, which are important cells during 
the innate immune response. Furthermore, SR-A recognizes bacterial cell wall 
products from gram-positive (lipoteichoic acid) (Dunne et al. 1994) and gram-
negative (lipopolysaccharide; LPS) (Hampton et al. 1991) bacteria. Taken
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together, expression on macrophages and recognition of bacterial products 
suggested a role for SR-A in host defense against bacterial infection. In vivo 
studies demonstrated that SR-A deficient mice are more susceptible to 
infection with gram-positive and gram-negative bacteria than wild-type mice. 
 
SR-A deficient mice are more susceptible to injection of gram-positive 
pathogens such as Listeria monocytogenes (Suzuki et al. 1997; Ishiguro et al. 
2001) and Staphylococcus aureus (Thomas et al. 2000). SR-A is thought to 
be protective from lethal gram-positive infection by recognition of lipoteichoic 
acid and consequent phagocytosis of the pathogens (Thomas et al. 2000). 
 
SR-A deficient mice were also more susceptible to endotoxic shock induced 
by LPS, the bacterial wall product of gram-negative bacteria. Therefore, SR-A 
was suggested to protect against lethal endotoxic shock by scavenging LPS 
(Haworth et al. 1997; Kobayashi et al. 2000). It has also been shown that SR-
A can not only bind, but also ingest gram-negative bacteria directly  (E. coli) 
(Peiser et al. 2000). 
 
Furthermore, SR-A has been shown to enhance host defense against herpes 
simplex virus type I (Suzuki et al. 1997) and repeated infestation with H. 
longicornis (Kabamoto et al. 2002). Finally, there is also evidence that SR-A is 
involved in adaptive immune response, as a role for SR-A in antigen 
presentation has been suggested (Nicoletti et al. 1999). 
 
7.3. Alzheimer's Disease 
Alzheimer's disease involves inflammatory processes and a pathological 
hallmark is the senile plaque. The senile plaque is characterized by 
accumulation of beta-amyloid fibrils, which exert cytotoxic effects on neurons, 
associated with microglia cells and astrocytes. In the normal brain, SR-A is 
only expressed on the perivascular cells surrounding arterioles (MATO cells) 
(Mato et al. 1996; Honda et al. 1998). However, in Alzheimer's disease SR-A 
is strongly expressed on microglia cells associated with senile plaques 
(Christie et al. 1996; Honda et al. 1998). SR-A mediates adhesion of microglia 
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cells to beta-amyloid fibrils resulting in the release of reactive oxygen species 
(El Khoury et al. 1996; El Khoury et al. 1998) and tumor necrosis factor (Meda 
et al. 1995). SR-A also has been shown to endocytose beta-amyloid fibrils 
(Paresce et al. 1996). Therefore, SR-A might play a role during Alzheimer's 
disease by modulating the inflammatory response and by scavenging beta-
amyloid fibrils.  
 
8. SR-A mediated adhesion 
SR-A mediated adhesion has been discovered during the development of the 
rat monoclonal antibody against murine SR-A, designated 2F8 (Fraser et al. 
1993). Unlike other cell lines, macrophages are able to attach to tissue culture 
plastic independent of divalent cations, which are required for integrin-
mediated adhesion.  2F8 was able to completely inhibit divalent-cation 
independent adhesion of macrophages to tissue culture plastic. This adhesion 
was dependent on the presence of fetal calf serum, suggesting that SR-A 
mediates adhesion to a component of fetal calf serum that is immobilized on 
the tissue culture plastic (Fraser et al. 1993). The same investigators also 
demonstrated that divalent-cation independent adhesion of macrophages to 
frozen tissue sections could be completely inhibited by 2F8 (Hughes et al. 
1995). In contrast to adhesion to tissue culture plastic, SR-A mediated 
adhesion to tissue sections did not require exogenous fetal bovine serum 
indicating that an endogenous adhesion substrate for SR-A is present within 
the tissues. 
 
Several substrates have been identified that might function as substrate for 
SR-A mediated adhesion in tissues.  SR-A mediated adhesion to modified 
extracellular matrix components prominent in the vessel wall has been 
described. These extracellular matrix proteins include collagen type IV, a 
component of the basement membrane, (el Khoury et al. 1994) and collagen 
type I  (Gowen et al. 2000) and type III (Gowen et al. 2001), which are the 
most abundant components of the extracellular matrix in the vessel wall. 
Interestingly, SR-A mediates adhesion specifically to modified forms of the 
collagens. Such modifications include denaturation and glycation, which are 
INTRODUCTION 19
associated with tissue injury. Furthermore, SR-A mediated adhesion to certain 
proteoglycans that are increased in atherosclerotic lesions has been 
described (Santiago-Garcia et al. 2003). SR-A mediated adhesion of microglia 
cells to beta-amyloid fibrils might occur within the plaques of Alzheimer's 
disease.  Thus, SR-A mediated adhesion might play an important 
physiological role by increasing macrophage retentention specifically at sites 
of tissue injury.  
 
SR-A mediated adhesion of macrophages may attenuate disease 
progresssion by increasing the retention of macrophages at specific sites. In 
addition to scavenging modified lipoproteins or beta-amloid fibrils, retained 
macrophages may influence the disease progression through release of 
inflammatory mediators, growth factors and matrix degrading enzymes. 
Despite the in vitro evidence supporting a role for SR-A mediated adhesion, a 
role of SR-A mediated adhesion has never been demonstrated in vivo.  
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II Specific Aims 
 
SR-A has been implicated in several disease processes through its ability to 
recognize and internalize a wide variety of ligands. However, SR-A also 
mediates cell adhesion. SR-A mediated adhesion may attenuate disease 
processes by increasing the retention of macrophages at sites of injury. 
However, the role of SR-A mediated adhesion in vivo is unclear.  Due to a 
lack of understanding of the structural requirements and the cellular 
mechanisms involved in SR-A mediated adhesion, it has not been possible to 
specifically address this process in vivo. The goal of my thesis project was to 
dissect SR-A mediated adhesion and ligand internalization and to develop a 
mutant of SR-A that lacks the adhesive properties.  Expression of such a 
mutant in SR-A deficient mice will then allow to define the role of SR-A 
mediated adhesion in vivo.  
 
Specific Aim 1: To characterize the functional consequences of macrophage 
specific SR-A overexpression in vitro. 
 
To address this aim, I studied lipoprotein internalization and the adhesive 
properties of peritoneal macrophages isolated from mice that overexpress 
SR-A under the control of a macrophage specific promoter (lyso-bSR-A mice) 
or from littermate control mice.  
 
Specific Aim 2: To identify the extracellular motif of SR-A that mediates 
adhesion.  
 
To address this aim, a SR-A specific adhesion assay that studies adhesion of 
the mouse macrophage cell line RAW.264 to collagenase-digested collagen 
type I was optimized. To identify the region of SR-A that contains the 
adhesion motif, fusion proteins homologous to different regions were used to 
compete for macrophage adhesion.  
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Specific Aim 3:  To identify a distinct cytoplasmic domain required for SR-A 
mediated adhesion. 
 
To address this aim, different cytoplasmic mutated SR-A constructs were 
expressed in HEK-293 cells and lipoprotein internalization and the adhesive 
properties of the cells were studied. 
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III Materials and Methods 
1. Materials 
1.1. Buffers and solution 
 
Ampicillin stock (100 mg/ml) 
1 g ampicillin  
Dissolve 10 ml dH2O 
Sterile filter and aliquot in 1 ml tubes 
Store at -20°C 
Do not freeze-thaw more than 5 times 
 
Luria broth (LB) 
10 g  peptone  
5 g  yeast extract 
5 g NaCl 
Dissolve in 1 L of dH2O 
Autoclave 
Store at 4°C 
 
Lysis buffer 
    25 mM (N-morpholino)ethanesulfonic acid (MES) 
150 mM NaCl 
   60 mM octylglucopyranoside 
1 % (v/v) Triton-X 100 
   pH 6.4 
   store at 4°C 
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Protease inhibitor cocktail (1x) 
500 mM  AEBSF 
150  nM  Aprotinin  
   1 mM E-64 
0.5 mM EDTA  
   1 mM  Leupeptin 
   Store as 100 x stock solution at -20°C 
 
5 x PBS 
6.25g   K2HPO4 
1.93 g  KH2PO4 
48.84 g NaCl 
Dissolve in 1l dH2O 
Store at 4°C 
 
1 x PBS 
Dilute 5 x PBS 1:5 (pH 7.4) 
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1.2. List of Manufacturers 
Accurate, Westbury, NY 
Amersham, Piscataway, NJ 
Beckman, Fullerton, CA 
Becton Dickinson, Franklin Lakes, NJ 
Bio-Rad, Hercules, CA 
Calbiochem, San Diego, CA 
Cellgro, Herndon, VA 
Fisher Scientifc, Pittsburgh, PA 
GibcoBRL Life Technologies, Grand Island, NY 
ICN, Costa Mesa, CA 
Invitrogen, Carlsbad, CA 
Jackson, West Grove, PA  
Pierce, Rockford, IL  
Promega, Madison, WI 
Millipore, Bedford MA  
Mirus, Madison, WI 
Molecular Probes, Eugene, OR 
Nalge Nunc International; Naperville, IL 
Novagen, Madison, WI  
PerSeptive Biosystems, Foster City, CA 
Roche, Nutley, NJ 
Santa Cruz, Santa Cruz, CA 
Sigma, St. Louis, MO 
Serotec, Raleigh, NC 
Stratagene, La Jolla, CA 
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2. Molecular biology 
2.1. Primer sequences 
The nucleotide sequences of the primers used to amplify murine SR-A 
(mouse strain BALB/C, gene bank accession number L04275) and murine 
TfR (gene bank accession number X57349) are shown in table 5.  Numbers 
after gene (SR-A or TfR) indicate the first (sense) or last (antisense) 
nucleotide of the gene bank nucleotide sequences amplified by the primer.  If 
the primers were designed to contain restriction sites, the restriction enzyme 
is stated and the restriction sites in the primer sequences are indicated in 
bold.  All primers were obtained from the Macromolecular Structure Analysis 
Facility at the University of Kentucky in lysophilized form. Primers were 
resuspended in dH2O to a final concentration of 100 pmol/l and stored at – 
20°C. 
 
Primer Restriction 
site 
Nucleotide Sequence 
SR-A     6         sense Hind III 5’ CGC GGG AAG CTT GCA ATG ACA AAA GAG ATG 3’ 
SR-A  153        sense Hind III 5’ CGC GGG AAG CTT GCA ATG GCT AAG TTG AAG TCC TTC AAG 3’  
SR-A  171        sense blunt 5’ GCT GCC CTC ATT GCT CTC TAC CTC CTT GTG 3’ 
SR-A  171        sense Hind III 5’ CGC GGG AAG CTT GCA ATG GCT GCC CTC ATT GCT CTC 3’ 
SR-A   348       sense  Sal I 5' CGC GGG GTC GAC TTT ACA ATT ATC ATG GCA 3'  
SR-A   834       sense Sal I 5' CGC GGG GTC GAC GGG CCT CCT GGA CCC CAA 3' 
SR-A   833 antisense Not I 5' CGC GGG GCG GCC GCT TGA ATG AAG GTG ATC TT 3'  
SR-A 1049 antisense Not I 5' CGC GGG CGC GGC CGC TAC ATC CCC CTT CTC 3'   
SR-A 1067 antisense Xho I 5’ GGG CTC GAG TTA TAC TGA TCT TGA TCC GCC 3’  
TfR          1      sense Hind III 5’ CGC GGG AAG CTT GCA ATG ATG GAT CAA GCC 3’ 
TfR     171  antisense blunt 5’ TCT GAC ACT AGC CTT CAT GTT ATT GTC GGC 3’  
 
Table 5:      Nucleotide sequences and generated restriction sites of primers.  
 
2.2. RNA Isolation 
Total RNA was isolated using the SV total RNA isolation system (Promega) 
according to the manufacturer’s protocol.  Briefly, by addition of the SV RNA 
lysis buffer (containing guanidine thiocyanate and -mercaptoethanol) the 
cells were lysed, cellular proteins denatured, nucleoprotein complexes 
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disrupted and nucleases present in the cell lysates inactivated.  Cell debris 
and denatured proteins were removed by centrifugation while the RNA 
remains in solution.  RNA is precipitated out of solution by addition of ethanol 
and then bound to a silica surface of glass fibers in a spin basket by 
centrifugation.  To digest contaminating genomic DNA, RNase-free DNAse I 
was added to the spin basket.  After washing with the SV RNA wash solution, 
the RNA is eluted from the spin basket in nuclease-free H2O.  The RNA 
concentration was determined as described (2.5.) and the RNA was stored at 
– 70°C. 
 
2.3. RT-PCR 
The Access RT-PCR system (Promega) was used for all RT-PCR reactions. 
This is a one tube, two-enzyme system, which allows reverse transcription of 
mRNA into cDNA and amplification of the cDNA in one reaction mixture. AMV 
reverse transcriptase transcribes the mRNA into cDNA (RT) and the 
thermostable Tfl DNA polymerase amplifies the cDNA (PCR). The reaction 
mixtures were prepared as shown in table 6 using 0.5 g of total RNA in a 
final reaction volume of 50 l. The parameters of the thermocycle reaction are 
shown in table 7. 
 
Reagent Volume Final concentration 
RNA in H2O  x l   
5x reaction buffer  10 l 1x  
Sense primer (100 pmol/l) 0.5 l 2 pmol/l  
Antisense primer (100 pmol/l) 0.5 l 2 pmol/l 
dNTP mixture (10mM each) 1 l 0.2 mM 
25 mM MgSO4 6 l 3 mM 
AMV reverse transcriptase  (5 u/l) 1 l 0.1 u/l 
Tfl DNA polymerase (5u/l) 1 l 0.1 u/l 
dH2O x l  
Final volume 50 l  
 
Table 6:  Reaction mixture for RT-PCR using the Access RT-PCR system 
(Promega).  
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Step Process Parameters Cycles 
1 RT 48°C for 45 min 1 
2 Denaturation  94°C for 2 min 1 
3 Denaturation  
Annealing 
Synthesis  
94°C for 30 s 
60°C for 60 s 
68°C for 120 s 
40 
4  hold at 4°C 1 
 
Table 7:  Parameters of the thermocycle reaction used for RT-PCR using 
the Access RT-PCR system (Promega).  
 
RT-PCR was used to amplify the cDNA encoding the mouse TfR from mouse 
liver RNA. RT-PCR was also used to assess mRNA expression of SR-A 
receptor constructs in HEK-293 cells with primers that amplify a fragment 
corresponding to the SR-A transmembrane and extracellular domains 
common to all SR-A constructs. The primers used for RT-PCR and are shown 
in table 8 (for primer sequences see 2.1. table 5). Reactions performed in the 
absence of RNA or reverse transcriptase were used as negative controls. RT-
PCR products were analyzed by agarose gel electrophoresis (2.6.). 
 
cDNA Sense primer Antisense primer Product 
TfR cyto TfR        1 Hind III TfR      171 blunt 171 bp        (1-171) 
SR-A1-55 SR-A 171 Hind III SR-A 1067 Xho I 897 bp  (171-1067) 
 
Table 8:  Primers used for RT-PCR and size of the cDNA product. Numbers 
in brackets indicate corresponding nucleotide of gene bank sequences (SR-A 
gene bank accession number L04275 and TfR gene bank accession number 
X57349). 
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2.4. PCR 
A master mix was used for PCR reactions (Promega). The reaction mixtures 
were prepared as shown in Table 9. The parameters of the thermocycle 
reaction are shown in table 10. 
 
Reagent Volume Final concentration 
DNA in H2O 1 l   
Sense primer (100pmol/l)  1 l  2 pmol/l 
Antisense primers (100pmol/l)  1 l  2 pmol/l 
2 x Mastermix: 
Taq Polymerase (50 Units/mL)  
MgCl (3mM) 
dATP, dCTP, dGTP, dTTP (400 M each) 
25 l  1x: 
0.025 units/l 
1.5 mM  
200 M 
dH2O 21 l  
Final volume 50 l  
 
Table 9:  Reaction mixture for PCR using a mastermix (Promega).  
 
Step Process Parameters Cycles 
1 Denaturation  94°C for 5 min 1 
2 Denaturation 
Annealing 
Synthesis 
94°C for 60 s 
60°C for 60 s 
72°C for 90 s 
35 
3 Final extension 72°C for 5 min 1 
4  hold at 4°C 1 
 
Table 10:  Parameters of the thermocycle reaction used for RT-PCR using 
the Access RT-PCR system (Promega). 
 
PCR was used to generate cDNA inserts to create expression vectors for 
fusion protein isolation from E. coli (pET23b) and for SR-A construct 
expression in HEK-293 cells (pcDNA5/FRT/TO). The primers used are shown 
in table 11 (for primer sequences see 2.1. table 5).  Reactions performed in 
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the absence of DNA were used as negative controls. PCR products were 
analyzed by agarose gel electrophoresis (2.6.). 
 
 cDNA Sense primer Antisense primer Product 
SR-A ahc+CL SR-A  348 Sal I SR-A 1049 Not I 702 bp  (348-1049) 
SR-A ahc  SR-A  348 Sal I SR-A  833  Not I 486 bp    (348-833) 
SR-A CL SR-A  834 Sal I SR-A 1049 Not I 216 bp  (834-1049) 
SR-A SR-A     6 Hind III SR-A 1067 Xho I 1067 bp      (6-1067) 
SR-A1-55 SR-A 171 Hind III SR-A 1067 Xho I 897 bp  (171-1067) 
SR-A1-49 SR-A 153 Hind III SR-A 1067 Xho I 915 bp  (153-1067) 
TfR cyto TfR        1 Hind III TfR      171 blunt 171 bp        (1-171) 
SR-A TM+EC SR-A 171  blunt SR-A 1067 Xho I 897 bp  (171-1067) 
 
Table 11:  Primers used to amplify SR-A and TfR cDNAs and size of the 
resulting product. Numbers in brackets indicate corresponding nucleotides of 
the SR-A (accession number L04275) and TfR (accession number X57349) gene 
bank sequences. ahc = -helical coiled coil; CL=collagen-like; TM= 
tranmembrane; EC=extracellular domain of SR-A type II. SR-A1-55 and SR-A1-49 
are the cDNAs encoding SR-A type II lacking the first 55 or 49 amino acids of 
the cytoplasmic tail.  
 
2.5. DNA and RNA concentration 
DNA and RNA concentration were determined by spectroscopy. Absorbances 
at 260 nm (A260) and at 280 nm (A280) were measured. To assess purity of the 
isolated RNA or DNA, the ratio A260/A280 was calculated. Pure RNA exhibits a 
A260/ A280 of 2.0. Pure DNA exhibits a A260/A280 of 1.8. A lower ratio indicates 
contamination with protein. A higher ratio indicates contamination with 
reagents used for isolation.  
 
An absorbance of 1.0 at A260 equals 50 g/l of DNA and 40 g/l of RNA. 
Therefore, the DNA and RNA concentration were calculated as follows: 
DNA concentration [g/l] = A260 x 50 x dilution factor 
RNA concentration [g/l] = A260 x 40 x dilution factor 
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2.6. Agarose gel electrophoresis 
 
TBE buffer (10x) 
890mM  Tris-borate 
890mM  boric acid 
   20mM   EDTA 
   pH 8.3 
   store at room temperature 
 
 TBE buffer (1 x) 
 Dilute 10 x buffer 1: 10 in dH20 
 
To analyze the size of the PCR and RT-PCR products, 5 l of the reaction 
volume were mixed with 1 l of 6x loading dye (Promega) and then separated 
on a 1 % agarose gel containing 0.02 % ethidium bromide (Fisher) in 1x TBE 
buffer (Promega). To determine product size the pGEM molecular weight 
marker was used (Promega). Electrophoresis was performed at 100 V for 
about 30 min using a horizontal electrophoresis chamber (Bio-Rad) filled with 
1 x TBE buffer. Ethidium bromide stained DNA was visualized using a Kodak 
Image Station 440. 
 
2.7. Restriction enzyme digest  
The cDNA inserts generated by RT-PCR or PCR were designed to create 
restriction sites that allow insertion into the multiple cloning site of the 
expression vector. The cDNA inserts and expression vector DNA (1 - 5 g) 
were digested with the respective restriction enzymes (Promega). For cloning 
into the pET23b vector (used for generating fusion proteins) the restriction 
enzymes Sal I and Not I were used in buffer D. For cloning into the 
pcDNA5/FRT/TO vector (used for SR-A construct expression in HEK-293 
cells) the restriction enzymes Hind III and Xho I were used in buffer C. Buffers 
were provided with the enzymes and in these buffers the activity of the 
enzymes is 75 – 100 %. To enhance enzyme activity, AcBSA was added at a 
final concentration of 100 g/mL. Per g of DNA 10 units of each restriction 
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enzyme (10 U/l) were used. Enzymes are provided in 50 % glycerol and for 
optimal enzyme activity the final glycerol concentration was kept < 5 % in the 
final volume of 50 -100 l. The digest was incubated at 37°C for 1 h. 
 
2.8. DNA purification 
To purify PCR products and digested vector DNA, the reaction mixtures were 
resolved by gel electrophoresis and the DNA was extracted from the gels 
using the rapid gel extraction kit (GibcoBRL) following the manufacturer’s 
protocol. To purify digested PCR products, the rapid PCR purification kit 
(GibcoBRL) was used following the manufacturer’s protocol.  
 
2.9.   DNA ligation 
The DNA Quick ligation kit (Roche) was used to ligate cDNA inserts into the 
expression vectors. Briefly, the digested and purified vector DNAs (100ng) 
and insert DNAs (vector DNA and insert DNA at a molar ratio of 1:3) were 
mixed in a total volume of 20 l containing 10 l of 2x DNA ligation buffer. 
After addition of 1 l T4 DNA ligase (5 U/l), the mixture was incubated for 30 
min at room temperature. To amplify the ligated vector DNA, E. coli JM109 
were transformed using the ligation mixture.   
 
2.10. Transformation of E.coli 
LB Agar plates  
6.4 g of powered LB agar  
Dissolve in 200 ml dH2O 
Autoclave 
Cool < 60°C and add 250 l ampicillin stock (125 g/ml) 
Store at 4°C 
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E. coli competent cells (Promega) were thawed on ice and 20 ul of cells were 
transferred into a pre-chilled 1.5 mL polypropylene Eppendorf tube. Then, 3 l 
of the ligation reaction or 1 - 5 ng of purified vector DNA was added and cells 
were kept on ice for 10 min. As positive control, transformation with 0.1ng/l 
non-digested vector DNA was performed. As negative control, transformation 
without vector DNA was performed. The cells were heat-shocked at 42°C for 
30 seconds and then kept on ice for 2 min Then, 80 l of S.O.C. medium were 
added. Cells were incubated in an orbital shaker at 225 rpm and 37°C for one 
hour to allow expression of the ampicillin resistance gene from the vector. 20 
and 50 l of the reaction were spread out on LB agar plates containing 
ampicillin (125 g/mL). The plates were incubated at 37°C overnight to allow 
growth of ampicillin resistant colonies. Colonies were screened by PCR for 
the presence of the inserts using the primers that were used to generate the 
inserts.  
 
2.11. Storage of E. coli  
80 % glycerol 
8 ml glycerol 
2 ml dH2O 
Autoclave 
Store at room temperature 
 
 
For storage of E.coli, glycerol stocks were prepared. E. coli containing the 
vectors were grown in 10 mL of LB the presence of selection antibiotics until 
the culture reached an optical density (OD) of OD600 = 0.6 – 0.8.  Then, 0.9 ml 
of cell suspension were transferred to a cryovial and 0.1 ml of 80% glycerol 
were added. Glycerol stocks were stored at – 70°C. 
 
2.12. Isolation of vector DNA 
E. coli colonies selected on LB Agar plates were inoculated in 10 mL LB 
containing ampicillin (100 g/ml) and grown overnight. Vector DNA was 
isolated from E.coli cultures using the Wizard Plus SV Minipreps DNA 
Purification System (Promega) according to the manufacturer’s protocol. The 
DNA concentration was determined and the DNA was stored at – 20°C. 
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2.13. Generation expression vectors 
a) PET23b for fusion protein expression in E. coli 
The PET23b vector of the pET system (Novagen) was used to generate 
fusion proteins homologous to the α-helical coiled-coil, to the collagen-like 
domain or to both of these domains of the murine scavenger receptor. The 
respective cDNA encoding the proteins were amplified by PCR with primers 
generating 5' Sal I and 3' Not I restriction sites. The primer sequences and 
product sizes are shown in table 5. 
 
After the correct product size was confirmed by agarose gel electrophoresis, 
the cDNA products were purified, digested with Sal I and Not I, and cloned 
into the PET23b expression vector. E. coli JM109 were transformed and 
selected on LB agar plates. Colonies were screened for cDNA inserts by PCR 
using the primers that were used to generate the inserts. Positive colonies of 
each insert were grown in LB overnight and vector DNA was isolated. The 
sequence of the inserts was confirmed at the Macromolecular Structure 
Analysis Facility at the University of Kentucky.  
 
b) pcDNA5/FRT/TO for SR-A construct expression vectors in HEK cells 
The pcDNA5/FRT/TO expression vector of the Flp-InTM T-RExTM system 
(Invitrogen) was used to generate HEK cells that express the different SR-A 
constructs. The cDNAs encoding full-length SR-A, SR-A lacking all 55 amino 
acids of the N-terminal cytoplasmic tail (SR-A1-55), and SR-A lacking the first 
49 amino acids of the cytoplasmic tail (SR-A1-49) were amplified by PCR from 
SR-A type II murine cDNA (gene bank accession no. L04275). The primers 
were designed to generate 5' Hind III and 3' Xho I restriction sites. The primer 
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sequences and products sizes are shown in Table 5. Deleting the cDNA 
encoding the amino-terminal amino acids eliminated the translation start 
codon. Therefore, the 5' PCR primers used to amplify SR-A1-55 and SR-A1-49 
were designed to insert a methionine translation start codon and a spacer 
alanine codon. To replace the cytoplasmic tail of SR-A with that of the 
transferrin receptor (TfR/SR-A), the cDNA encoding the N-terminal 57 amino 
acids of the murine transferrin receptor (gene bank accession no. X57349) 
was amplified by RT-PCR from RNA isolated from mouse liver and inserted 5' 
to the cDNA encoding the SR-A transmembrane and extracellular domains.  
  
The RT-PCR and PCR products were resolved by agarose gel 
electrophoresis. After the correct product size was confirmed, the cDNA 
products were purified, digested by the appropriate restriction enzymes, and 
cloned into pcDNA5/FRT/TO expression vector (Invitrogen). The sequence of 
the inserts was confirmed at the Macromolecular Structure Analysis Facility at 
the University of Kentucky. The amino acids sequences of the receptor 
constructs are shown in Table 14. 
 
3. Generation of fusion proteins 
 
IPTG (100 mM) 
2.38 g IPTG  
Dissolve in 100 ml dH2O 
Store at -20°C 
 
Fusion proteins homologous to the α-helical coiled-coil, the collagen-like 
domain or both of these domains of the murine scavenger receptor were 
generated using the Novagen pET system. An overview of the system is 
shown in Figure 5. The cDNAs, which are the target genes, encoding the SR-
A domains, were cloned into the PET23b expression vector and transformed 
into E. coli BL21(DE3) host cells as described in the molecular biology 
section. Expression of the target gene is under the control of the T7 RNA 
polymerase promoter. E.coli BL21 (DE3) host cells carry the T7 RNA 
polymerase gene (DE lysogen). The T7 RNA polymerase and the target gene 
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expression are under the control of the lac repressor, which is expressed 
constitutively from the E. coli genome. Therefore, expression of the target 
gene is induced by addition of the lactose analogue IPTG (0.4 mM) to the 
growth medium. Expression of the target gene results in His•Tag fusion 
proteins (6 consecutive histidine residues).  
 
 
 
Figure 5:  Overview of the pET expression system used to express fusion 
protein homologous to SR-A domains.  Expression of the target gene in the E. 
coli host cells is induced by addition of IPTG. 
 
Cells transformed with the expression vectors were grown in 200 ml LB until 
the culture reached an optical density (OD) of OD600 = 0.5 – 1.0.  Fusion 
protein expression was induced for 3 h by addition of IPTG (0.4 mM) to the 
broth. To isolate the expressed fusion protein, the cells were separated from 
the broth by centrifugation at 1,000 g for 10 min. To confirm fusion protein 
expression, cell lysates were separated by SDS-PAGE and fusion proteins 
were detected by Western blotting with a His•Tag antibody (Santa Cruz).  
MATERIALS AND METHODS 36
 
 
After expression was confirmed, the fusion proteins were isolated from the cell 
lysates by immobilized metal affinity chromatography using His•bind quick 
columns (Novagen). The His•Tag sequence of the fusion proteins binds to 
divalent cations (Ni2+ ) immobilized on His•Bind resins of the columns. After 
unbound proteins are washed away, the fusion proteins are recovered by 
elution with imidazole and dialyzed against PBS.  
 
4. Protein chemistry 
4.1. Preparation of cell lysates 
Cell lysates of HEK-293 cells were prepared by incubating cells in lysis buffer 
for 30 min on ice in the presence of protease inhibitors (Calbiochem). After 
lysis, insoluble material was removed by centrifugation at 13,000 g for 10 min 
and the supernatant was transferred to a fresh tube. 
 
4.2. Protein concentration 
Protein concentrations of the cell lysates were determined based on the 
Lowry assay (Lowry et al. 1951) using a colorimetric assay according to the 
manufacturer’s instructions (DC Protein Assay, Bio-Rad). Absorption of 
samples was measured at 655 nm using a microplate reader (Bio-Rad). 
Bovine serum albumin at concentrations between 0.1 mg/ml and 1.6 mg/ml 
was used to generate a standard curve. All samples and standards were 
assayed in duplicate.  
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4.3. Immunoprecipitation 
In some experiments, SR-A receptors were immunoprecipitated from cell 
lysates or culture media using the rat SR-A monoclonal antibody, 2F8 (3 
g/ml; Serotec) and anti rat IgG-coated magnetic beads (PerSeptive 
Biosystems). Briefly, cell lysates were adjusted to 200 l in lysis buffer 
containing protease inhibitors (Calbiochem). 2F8 was added one hour before 
addition of 50 l anti rat IgG-coated magnetic beads. Samples were incubated 
overnight rotating at 4°C to allow formation of the antigen-antibody-complexes 
bound to the beads. The beads were pelleted by centrifugation at 2,000 rpm 
for 5 min at 4°C.  After washing twice in 1 ml lysis buffer containing protease 
inhibitors, 25 l of reducing sample buffer were added to the bead pellet. 
Samples were boiled at 100°C for 10 min and resolved by SDS-PAGE. 
 
4.4. Biotinylation of cell surface proteins 
Cells were plated in 6-well plates (0.5 x 106 cells/well) in DMEM/FBS and 
induced. Induced cells were trypsinized, transferred into 1.5 mL eppendorf 
tubes, washed twice in 1 ml ice-cold PBS. To prevent internalization, cells 
were kept on ice. Cell surface proteins were biotinylated in suspension (1 
mg/ml EZ-Link sulfo-NHS-LC-Biotin in PBS, Pierce) at 4°C for 30 min 
according to the manufacturer's instructions. To remove non-bound biotin, 
cells were washed with three times with ice-cold PBS. Subsequently, cell 
lysates were prepared and adjusted to 200 l in lysis buffer containing 
protease inhibitors. Biotinylated surface proteins were precipitated from 
lysates using streptavidin-coated magnetic beads (PerSeptive Biosystems). A 
volume of 50 l of beads was added to the cell lysates and incubated rotating 
at 4°C overnight. Cell surface proteins (bead pellet) and intracellular proteins 
(supernatant) of the precipitation were resolved under reducing conditions by 
SDS-PAGE and SR-A was detected by Western blotting. 
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4.5. N–glycanase (PNGase F) and endoglycosidase H digestion 
 
To cleave all N-linked oligosaccharides, cell lysate protein (10 g) was 
digested with N-glycanase (PNGase F; Sigma) in buffer (50 l; 50 mM 
NaHPO4, 0.1% SDS, 0.05 M -mercaptoethanol, pH 7.5) according to the 
manufacturer's protocol. Briefly, proteins were denatured by heating to 100°C 
for 5 min.  After cooling, Triton X-100 (0.75% v/v) and N-glycanase were 
added and the reaction was incubated for 3 h at 37°C.  
 
To cleave precursor N-linked oligosaccharides, cell lysate protein (10 g) was 
digested with endoglycosidase H (EndoH, Sigma) in buffer (50 l; 50 mM 
NaHPO4, 0.1% SDS, 0.05 M -mercaptoethanol, pH 5.5) according to the 
manufacturer's protocol, which was identical to that used for N-glycanase 
digestion with the exception of the addition of Triton X-100. 
 
4.6. SDS-PAGE 
 
10 % SDS  
10 g sodium docecyl sulfate (SDS) 
Dissolve in 100 ml dH2O 
 Store at room temperature 
 
1.5 M Tris 
 7.38 g Tris HCl 
 30.78 g Tris base 
 Dissolve in 200 ml dH2O 
 pH 8.8 
 Store at 4°C 
 
0.5 M Tris  
12.0 g Tris base 
 Dissolve in 200 ml dH2O 
pH 6.8 
 Store at 4°C 
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20 % APS (wt/v)  
0.2 g ammonium persulfate 
 Dissolve in 1.0 ml dH2O 
 Store at 4°C 
 
Running buffer (10 x)  
30 g Tris 
 144 g Glycine 
 10 g SDS 
 Dissolve in 1 l dH2O 
 Store at room temperature  
 
Running buffer (1 x)  
dilute 50 mL of 10 x running buffer to 500 mL with dH2O 
 
Sample buffer, reducing (2 x) 
6.0 ml dH2O 
0.5 ml 0.5 M Tris, pH 6.8 
1 ml glycerol 
1 ml SDS (10 % w/v) 
0.75 ml bromophenol blue  
0.2 ml -mercaptoethanol 
Store at 4°C 
For non-reducing buffer omit -mercaptoethanol 
 
Proteins were resolved by discontinuous SDS-polyacrylamide gel 
elecrophoresis (SDS-PAGE) using the MINI-PROTEAN II System (BioRad). 
By the addition of SDS, an anionic detergent, proteins are denatured and 
charged negatively. Thus, proteins are separated independent of charge 
based on their molecular weight. Proteins were resolved under reducing or 
non-reducing conditions as indicated. The resolving gel was overlayed with a 
stacking gel. The preparation of the gels is shown in table 12. The gel 
electrophoresis was run at 50 V until the samples reached the stacking gel. 
Then, the voltage was increased to 130 V and electrophoresis was continued 
until the loading dye reached the bottom of the resolving gel. Prestained 
markers were used to determine the molecular weight (BioRad).   
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Separating gels (20 ml) 
Percent Acrylamide/bis 1.5 M Tris H2O 10 % SDS 20 % APS TEMED 
7.5 2.5  4.9 
15 5  
2.5 
2.4 
100 l 30 l 60 l 
Stacking gels (5 ml) 
Percent Acrylamide/bis 0.5 M Tris H2O 10 % SDS 20 % APS TEMED 
4 0.65 1.25 3.05 50 l 30 l 60 l 
 
Table 12:  Preparation of separating and stacking gels for SDS-PAGE. All 
volumes are ml unless stated otherwise. The final volumes are sufficient for 
two minigels. APS and TEMED are added last for polymerization of the gels. 
 
4.7. Western blotting 
 
Primary antibodies 
Antibody Antigen Raised in  Dilution 
2F8 SR-A Rat 3 g/ml 
SR-A antiserum  SR-A Guinea pig  1:100 
His•Tag His•Tag Rabbit 1:1,000 
Secondary antibodies 
Antibody Antigen Raised in  Dilution 
Anti rat Rat IgG Goat 1:10,000 
Anti guinea pig Guinea pig IgG Goat 1:10,000 
Anti rabbit Rabbit IgG Goat 1:10,000 
 
Table 13:  Antibodies used for Western blotting. All antibodies were diluted 
in TNT.  
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Transfer buffer 
3 g  Tris base 
14.4 g  glycine 
 Dissolve in 800 ml dH2O 
 Add 200 ml methanol 
 Store at 4°C 
 
TNT  
10 mM Tris  10 ml 500 mM pH 8.0 
140 mM NaCl  15 ml 5M  
0.1 % Tween 20 (v/v) 500 l  
   Dilute to 500 ml dH2O 
   Store at room temperature 
 
Blocking solution 
1.25 g dry milk  
25 ml  TNT 
 
Proteins resolved by SDS-PAGE were transferred to polyvinylidene fluoride 
(PVDF) membranes (Millipore) by electrophoresis at 100 V (300 – 400 mA) for 
90 min on ice. To enhance protein binding to the membranes, the membranes 
were dried after the transfer.  
 
Antigens bound to the membrane were detected by Western blotting as 
follows. All steps were performed at room temperature using an orbital 
shaker. Dried PVDF membranes were rewetted in ethanol and soaked in 
dH2O for 5 min.  Then, the membranes were blocked with dry milk (5% wt/v) 
in TNT for 30 min.  Membranes were incubated with primary antibodies for 20 
min. SR-A receptor proteins resolved under reducing conditions were 
detected using a guinea pig antiserum developed to a fusion protein of the 
extracellular SR-A domain as described previously (Daugherty et al. 2000). To 
detect oligomeric forms of the receptors, cell lysates were resolved under 
non-reducing conditions and receptor proteins detected with 2F8 (3 g/mL, 
Serotec), which also recognizes an extracellular epitope of SR-A (Daugherty 
et al. 2000). His•Tag labeled fusion proteins were resolved under reducing 
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conditions and detected with a rabbit anti His•Tag antibody. After washing 5 
times for 2 min in TNT. Primary antibody binding was detected by incubation 
with horseradish peroxidase labeled secondary antibodies (Jackson; 1:10,000 
dilution). After washing 5 times for 2 min in TNT, horseradish peroxidase 
activity was visualized by enhanced chemiluminescense (ECL; Pierce) using 
a Kodak Image Station 440. 
 
4.8. Immunofluorescence 
 
Cells were plated on 2-chamber (50,000 cells/chamber) LAB-TEK glass slides 
(Nalge Nunc International) and receptor proteins were detected as previously 
described (Post et al. 2002). Briefly, cells were induced where indicated, 
washed twice with phenol-red free DMEM (37°C), fixed in paraformaldehyde 
(4 % w/v), and permeabilized with Triton-X (0.1 % v/v in PBS). Nonspecific 
binding sites were blocked by incubation with BSA (1% w/v in PBS) for 30 
min. To detect expressed receptors, cells were incubated with 2F8 (3 ug/mL 
in PBS; Serotec) for 15 min. After washing twice with PBS, primary antibody 
binding was detected by incubation with an Alexa-Fluor488 labeled goat anti-
rat antibody (2 g/mL in PBS; Molecular Probes) for 20 min. Cell nuclei were 
stained with DAPI (300 nM in PBS; Molecular Probes) for 5 min. After 
washing twice in PBS, cells were mounted in Mowiol embedding medium 
(37°C) containing n-propyl gallate (1% w/v), cover slipped and dried 
horizontally overnight at 4°C.  Images were captured digitally by fluorescence 
microscopy (Excitation filter 465 – 495) with constant exposure times.  
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5. Lipoprotein isolation and modification 
 
EDTA/saline solution  
1 mM  EDTA 
0.15 M  NaCl  
pH 7.4  
Store at room temperature 
 
LDL (d = 1.019 – 1.063 g/ml) was isolated by sequential ultracentrifugation of 
EDTA-anticoagulated plasma obtained from healthy normolipidemic 
volunteers (Havel et al. 1955). 
5.1. VLDL and IDL 
The first step is isolation of the VLDL and IDL fraction (d < 1.019 g/ml). The 
density of the plasma (d = 1.006) is adjusted to 1.019 by addition of KBr 
(17.14 mg/ml). After adjusting the density, the plasma is transferred into 
ultracentrifuge tubes (Beckman) and spun at 40,000 rpm at 10 °C for 18 h in a 
Beckman ultracentrifuge. A phase separation will occur. The white top phase 
(d < 1.019) contains the VLDL and IDL particles. This phase is removed and 
discarded. The lower yellow phase (d > 1.019) contains LDL, HDL and 
proteins.  
5.2. LDL 
The lower phase (d > 1.019) is transferred into a measuring cylinder and the 
density is adjusted to 1.063 by addition of KBr (58.78 mg/ml). After adjusting 
the density, the plasma is transferred into ultracentrifuge tubes (Beckman) 
and spun at 50,000 rpm at 10 °C for 18 h. Again, a phase separation will 
occur. The top yellow phase (d = 1.019 – 1.063) contains the LDL particles. 
To further purify the LDL containing phase, the top yellow phase is transferred 
into a fresh centrifuge tube and mixed with EDTA/saline solution adjusted to d 
= 1.063 (80.77 mg/ml KBr) and centrifuged as above. The purified top phase 
is then transferred into dialysis tubing (Spectrum) and dialyzed against 
EDTA/saline (d = 1.006) with at  
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least three changes of the EDTA/saline at 4 °C. After dialysis LDL is filter 
sterilized (0.22 m pore size) and the protein concentration is determined by 
Lowry assay after delipidation of the sample.  
5.3. Preparation of acetylated LDL 
 
Saturated sodim acetate: 
0.574 g sodium acetate 
Dissolve in 1 ml dH2O 
 
Acetylated LDL (AcLDL) was prepared by chemical modification of LDL with 
acetic anhydride (Fisher) as described by Basu et al.. (Basu et al. 1976). LDL 
(1 ml), isolated as described above (5.2), was placed into a glass tube 
(16x100) and an equal volume of saturated sodium acetate solution was 
added. During constant stirring on ice, acetic anhydride (2.5 l) was added at 
0, 15, 30, 45 min of incubation and incubation was continued for another 30 
min. Acetylation was confirmed by agarose gel electrophoresis and 
comparison to unmodified LDL. As described for LDL, acetylated LDL was 
dialyzed against EDTA/saline, sterile filtered and the protein concentration 
was determined.  
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6. Cell culture 
 
All cells were cultured in Dulbecco's modified Eagle's medium (DMEM; 
GibcoBRL) containing glutamine (1%), penicillin (10 U/ml), streptomycin (10 
g/ml) and heat-inactivated fetal bovine serum (10% FBS; GibcoBRL) 
(DMEM/FBS) unless stated otherwise. Cells, culture reagents, and materials 
were handled under sterile conditions. Cells were cultured in a humidified 
incubator with 5 % CO2/95 % air at 37°C. 
 
6.1. Mouse peritoneal macrophages 
Mouse peritoneal macrophages were harvested by peritoneal lavage. Mice 
were anesthetized and sacrificed by cervical dislocation. The outer skin was 
cut and 5 ml of ice-cold sterile saline were injected into the peritoneal cavity 
through the intact abdominal musculature with a 5 ml syringe and an 18-
gauge needle.  The saline was slowly withdrawn back into the syringe and 
transferred into a conical tube on ice. Macrophages were spun down by 
centrifugation at 300 g for 15 min at 4°C, washed and plated for experiments 
in tissue culture dishes or onto glass slides in DMEM/FBS.  
 
6.2. RAW.264 
The mouse macrophage cell line RAW.264 was cultured in about 13 ml of 
DMEM/FBS in T-75 tissue culture flasks. When the cells reached about 80 - 
90 % confluency, cells were scraped and resuspended in 10 mL and 1 ml of 
the cells suspension (1:10 split) was transferred into a fresh T-75 flask 
containing 12 ml media.   
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6.3. HEK-293 expressing SR-A constructs 
a) HEK-293 host cells 
To generate cells that express the different SR-A constructs, we used the Flp-
InTM T-RExTM system (Invitrogen). An overview of the system is shown if 
Figure 5. This system allows tetracycline-inducible expression after integration 
of the cDNA into a specific genomic site. An important advantage of this 
system is that similar levels of expression can be obtained upon induction of 
cells transfected with the different SR-A constructs.  Flp-InTM T-RExTM HEK-
293 host cells were used, as HEK-293 cells do not endogenously express 
SR-A and have been used previously to study SR-A function (Post et al. 
2002). 
 
HEK-293 host cells were cultured in T-75 tissue culture flasks in 13 ml 
DMEM/FBS containing the selection antibiotics blasticidin (15 g/ml) and 
zeocin (100 g/ml).  When the cells reached a confluency of about 80 -90 %, 
cells were detached by incubation in 5 mL Trypsin/EDTA for 5 - 10 minutes. 
Trypsin activity was stopped by addition of 5 mL DMEM/FBS. The cell 
suspension was transferred into a 15 ml centrifuge tube and the cells were 
spun down by centrifugation at 300 g for 5 min. The cells were resuspended 
in 10 ml DMEM/FBS containing selection antibiotics and 1 ml of the cells 
suspension (1:10 split) was transferred into a fresh T-75 flask with 12 ml 
DMEM/FBS containing selection antibiotics. For transfection cells were plated 
(day 1 of transfection procedure) into 6-well plates in 2 ml (5 x 105/well).  
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Figure 6:  Overview of the Flp-InTM T-RExTM expression system used to 
generate HEK-293 cells expressing the different SR-A constructs.   
 
b) Transfection and selection of HEK-293 cells 
Approximately 24 hours after plating (day 2), HEK-293 host cells were co-
transfected with the vectors pcDNA5/FRT/TO (0.2 g) containing the SR-A 
constructs and pOG44 (1.8 g), encoding Flp recombinase, which mediates 
insertion of pcDNA5/FRT/TO into the genomic integration site, using the 
TransIT-293 transfection reagent according to the manufacturer's protocol 
(Mirus). Briefly, 6 l of the TransIT-293 reagent were added to 244 l DMEM, 
mixed by vortexing and incubated for 5 min. In a separate tube, the vector 
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DNAs were mixed in 250 l DMEM. The two mixtures were combined, mixed 
by gentle pipetting and incubated at room temperature for 20 min to allow the 
TransIT-293/DNA complex to form. This mixture was added dropwise to the 
HEK-293 host cells. The cells were incubated with the TransIT-293/DNA 
complex for 24 h. On day 3, the transfection media was replaced with 
DMEM/FBS containing blasticidin (15 g/ml). After transfection, Flp 
recombinase is expressed and mediates integration of the pcDNA5/FRT/TO 
into the genome. Integration of pcDNA5/FRT/TO eliminates zeocin resistance 
and confers hygromycin B resistance. Thus, transfected cells were selected 
for stable integration of the SR-A constructs into the genome with hygromycin 
B (200 g/ml) starting on day 4. The selection media was changed every 2 - 3 
day and resistant colonies appeared about 2 weeks after tranfection. 
Tranfected cells were cultures are described for host cells in DMEM/FBS 
containing the selection antibiotics blasticidin (15 g/ml) and hygromycin B 
(100 g/ml).  
 
c) Induction of construct expression of HEK-293 
Receptor construct expression was induced by adding tetracycline to the 
culture media for 16 h unless stated otherwise. A tetracycline stock solution 
(1mg/ml) was prepared in ethanol and stored protected from light at - 20°C. 
Concentration response studies showed that a concentration of 0.5 g/ml 
tetracycline induced maximal protein expression (data not shown). 
d) Storage of cells    
When cells were passage into a new T-75 flask as described above, 0.7 ml of 
the 10 ml cell suspension was transferred into 1.5 ml cryovials containing 0.2 
ml FBS and 0.1 ml DMSO.  The cells were stored at - 70°C for 24 h and then 
transferred into liquid nitrogen.  
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7. Cholesterol ester synthesis in peritoneal macrophages 
Isolated peritoneal macrophages were incubated with the stated 
concentrations of AcLDL protein/ml and 3H-oleate (0.1 mM; Amersham) 
complexed with fatty acid-free BSA in a molar ratio of 5:1 for 5 h at 37°C in 
DMEM. The media was removed, and the cells were washed twice with ice-
cold Tris buffer (pH 7.4). Cellular lipids were extracted by two 30-min 
incubations with 1ml hexane–isopropanol (3:2, v/v) containing carrier lipid 
(triolein and cholesterol palmitate). The lipid extracts were dried under 
nitrogen, redissolved in chloroform-methanol (2:1, v/v), and separated by thin-
layer chromatography with petroleum ether:diethyl ether:acetic acid 84:15:1 
(v/v/v). Esterified cholesterol was identified by exposure to iodide vapor, 
scraped into EcoLite scintillation fluid (ICN). Cholesteryl 3H-oleate was 
quantified by liquid scintillation counting using a Beckman LS 3801 counter. 
Cell proteins were solubilized in 0.5 ml 0.1 N NaOH for 16 h at room 
temperature and protein content was determined using the Bio-Rad Dc protein 
assay (Bio-Rad). The amount of cholesteryl 3H-oleate was normalized to cell 
protein.  
 
8. Spreading of peritoneal macrophages 
Peritoneal macrophages isolated from lyso-bSR-A transgenic or non-
transgenic littermate mice were resuspended in DMEM/FBS and plated on 8-
well LabTek glass slides (105 cells/well) for up to 24 hrs and fixed with 4 % 
paraformaldehyde. After non-specific binding sites were blocked with non-
immune goat serum (15 l/ml), cells were immunostained with a rabbit 
antiserum to mouse macrophages (1:1,000 dilution; Accurate). Primary 
antibody binding was detected with a biotinylated goat anti rabbit secondary 
antibody (1:200 dilution; Vector). Antibody binding was visualized using the 
ABC Kit (Vector) and the red chromogen ACE. The area of cells was 
quantified using Image Pro software.  
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9. RAW.264 macrophage adhesion assay 
We modified an assay described by Gowen and colleagues to investigate SR-
A mediated macrophage adhesion (Gowen et al. 2000). Collagen type I 
coated 96-well plates (Becton Dickinson) were digested with collagenase (2.5 
g/mL PBS, Sigma) for 30 min at 37°C and then washed three times with PBS 
(200 l). RAW 264 macrophages were washed and resuspended to a final 
density of 1.5 x 106 cells/ml in Hanks buffered saline solution (HBSS) devoid 
of divalent cations (Cellgro). Incubation in the absence of divalent cations will 
eliminate integrin-mediated adhesion, as integrin-mediated adhesion is 
dependent on divalent cations. To each well 100 l of cell suspension (1.5 x 
105 cells/well) were added and incubated for 60 min at 37°C to allow cells to 
adhere. Non-adherent cells were removed by washing three times with PBS 
(200 l). Adherent cells were fixed in 4 % paraformaldehyde (200 l/well) for 
15 min and stained with hematoxylin (50 l/well) for 5 min. Fixed and stained 
cells were washed with PBS (200 l) twice and kept in PBS (100 l) for 
analysis. Adhesion was quantified by counting cells per field at 10x 
magnification using a light microscope and ImagePro Software.  
 
To inhibit SR-A mediated adhesion, the cells were incubated with the rat 
monoclonal antibody against SR-A, 2F8 (Serotec), or antagonists of the SR-A 
specific ligand acLDL, polyinosine and fucoidan, at the stated concentrations 
for 15 min at room temperature before the cells were added to the wells. As 
negative controls, cells were incubated with an isotype-matched antibody (rat 
IgG2b, Serotec) or structurally similar compounds of the antagonists 
polycytidine and chondroitin respectively at the same concentrations and 
conditions. To investigate whether a fusion protein homologous to the 
extracellular domain can compete for SR-A mediated cell adhesion, the fusion 
protein was added to the modified collagen coated wells at the stated 
concentrations in 50 l PBS and incubated for 30 min before addition of the 
cells.   
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10. Tunicamycin and brefeldin A treatment of HEK-293 cells 
To inhibit N-linked glycosylation in the endoplasmic reticulum (ER), HEK-293 
cells were cultured in presence of tunicamycin (5 g/ml, Sigma). To inhibit 
maturation of N-linked oligosaccharides in the Golgi apparatus, HEK-293 cells 
were cultured in presence of brefeldin A (5 g/ml, Sigma). These inhibitors 
were added 60 min before inducing cells with tetracycline and were present 
throughout induction. Cell lysates were prepared 6 h after addition of 
tetracycline. 
 
11. AcLDL internalization of HEK-293 cells 
Cells were plated into 6-well plates (0.5 x 106 cells/well) in DMEM/FBS and 
induced. Following incubation of induced cells in serum-free DMEM for 2 h, 
fluorescently labeled AcLDL (2.5 g/ml, Alexa-Fluor488 AcLDL, Molecular 
Probes) was added to the media and incubation was continued for another 2 
h. Cells were trypsinized with 0.5 ml T/E, washed twice with 2 ml ice cold PBS 
and resuspended in 200 l PBS for analysis. AcLDL internalization was 
assessed by quantifying cell-associated fluorescence (Flow Cytometry Core 
Facility, University of Kentucky). Fluorescence was gated for individual live 
cells and the fluorescence associated with approximately 20,000 cells 
determined for each sample. To assess non-specific AcLDL cell-association, 
polyinosine (10 g/ml) was added 5 min before addition of fluorescently-
labeled AcLDL. 
12. Cell adhesion assay of HEK-293 cells 
HEK-293 cells were plated in 96-well plates (2 x 104 cells/well) in DMEM/FBS 
and induced where indicated. Adhered cells were incubated in EDTA-solution 
(0.2 g/ml, 37°C) for 10 min to eliminate divalent-cation dependent adhesion. 
After washing with PBS (37°C), cells remaining adhered were quantified using 
the CyQUANT assay (Molecular Probes) according to the manufacturer's 
instructions. To normalize cell adhesion to the total number of cells plated, an 
untreated plate was analyzed.  
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IV Results 
1. Macrophages from SR-A transgenic mice 
 
To better understand the role of SR-A expressed on macrophages in vivo, 
transgenic mice that express bovine SR-A (bSR-A) under the control of the 
macrophage specific lysozyme promoter (lyso-bSR-A) were generated 
(Daugherty et al. 2001). To assess the functional consequences of lyso-bSR-
A expression, SR-A mediated ligand internalization and cell adhesion of 
peritoneal macrophages from lyso-bSR-A transgenic mice were compared to 
those of peritoneal macrophages from nontransgenic littermate mice.  
 
To assess SR-A mediated internalization, I determined cholesterol ester 
synthesis in response to AcLDL. Cultured peritoneal macrophages were 
incubated with 3H-oleate in the presence or absence of AcLDL (5 g/ml) for 5 
h. Then, lipids were extracted from the cells and separated by thin layer 
chromatography. Cholesterol ester synthesis was determined by quantifying 
the radioactivity of 3H-oleate incorporated into cholesterol ester.  AcLDL 
increased cholesterol ester synthesis in macrophages isolated from 
nontransgenic mice by 5-fold (figure 7). This increase was augmented by 2-
fold in macrophages isolated from transgenic mice. This finding demonstrates 
that lyso-bSR-A expression enhanced SR-A mediated ligand internalization. 
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Figure 7: Peritoneal macrophages from non-transgenic (black bars) and 
lyso-bSR-A transgenic (white bars) littermates were incubated with AcLDL and 
3H-oleate at 37°C for 5 hours. Cholesterol esters were extracted and 
radioactivity content was quantified. Histobars represent the mean of six 
observations from two experiments, and bars represent the SEM. * P < 0.001 
 
To assess the SR-A mediated cell adhesion, I anaylzed cell spreading of 
peritoneal macrophages in culture.  Peritoneal macrophages isolated from 
SR-A deficient mice adhered weakly and did not spread when cultured on 
glass for 24 h, whereas those from the wild-type mice adhered tightly and 
displayed a spread morphology (Suzuki et al. 1997). To investigate whether 
macrophages isolated from lyso-bSR-A mice display enhanced cell spreading, 
I cultured peritoneal macrophages from SR-A transgenic mice on glass slides. 
After 3, 6 and 24 h cells were fixed and immunostained with a macrophage 
antiserum. By visual inspection macrophages from transgenic mice appeared 
more spread than those from nontransgenic mice at all time points (Figure 8A 
and B). Quantification of the area of the cells confirmed this observation 
(Figure 8C). After 24 h, there were a significantly increased number of 
macrophages with an area greater than 400 µm2 (P < 0.001). The increased 
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cell spreading of macrophages from lyso-bSR-A transgenic mice 
demonstrates that lyso-bSR-A expression enhanced SR-A mediated 
adhesion. 
 
 
Figure 8:   Peritoneal macrophages from non-transgenic (A) (black bars) 
and lyso-bSR-A transgenic (B) (white bars) littermates were cultured for 24 h 
on glass slides, immunostained with a macrophage antiserum and surface area 
was quantified (C). *  P < 0.001 
 
Taken together, our in vitro results demonstrate that lyso-bSR-A transgenic 
mice have increased macrophage SR-A activity. SR-A overexpression 
enhanced ligand internalization and cell spreading of peritoneal macrophages 
and both processes might occur in lyso-bSR-A mice in vivo.  
 
Subsequent in vivo studies were performed to address the role of enhanced 
macrophage SR-A activity of lyso-bSR-A transgenic mice in a model of 
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inflammation (Daugherty et al. 2001). These studies found that lyso-bSR-A 
expression significantly increased the development of carrageenan-induced 
granulomas. Importantly, this increase was due to increased number of 
macrophages and not due to enhanced lipid deposition. This finding 
demonstrated that SR-A expression is associated with increased macrophage 
retention/recruitment during inflammatory processes in vivo and supports an 
important physiological role of SR-A mediated adhesion.  
 
RESULTS 56
2. The extracellular domain of SR-A that mediates adhesion 
 
SR-A mediated adhesion may play an important physiological role. Using SR-
A transgenic mice, I have shown that increased SR-A expression enhanced 
macrophage spreading in vitro. This finding suggested that SR-A can increase 
macrophage adhesion. Subsequent studies in our laboratory using these 
transgenic mice have shown increased macrophage retention/recruitment in a 
model of inflammation in vivo (Daugherty et al. 2001). Furthermore, several 
extracellular matrix components that are associated with sites of tissue injury 
including modified types of collagen and certain proteoglycans have been 
identified as adhesion substrates for SR-A (el Khoury et al. 1994; Gowen et 
al. 2000; Santiago-Garcia et al. 2003). Therefore, SR-A mediated adhesion 
may play an important role in retention of macrophage at sites of tissue injury.  
 
To be able to address the role of SR-A mediated adhesion specifically, I 
performed studies in order to identify the extracellular motif that mediates 
adhesion. I optimized an SR-A dependent adhesion assay described 
previously by Gowen et al.. (Gowen et al. 2001). RAW.264 macrophages 
adhere weakly to fibrillar (native) collagen type I. However, these cells 
displayed enhanced adhesion to monomeric, heat-denatured and 
collagenase-treated collagen type I collagen. The adhesion was independent 
of divalent-cations and could be blocked by 2F8 and the SR-A ligand dextran 
sulfate. Initial studies have shown that SR-A mediated adhesion to serum-
coated surface can be completely blocked by 2F8. I studied adhesion of 
RAW264 macrophages to collagenase-treated collagen type I in serum-free 
and divalent cation-free HBSS. 
 
RAW264 macrophages were incubated in 96-well tissue culture plates coated 
with collagenase-treated collagen type I.  After one hour, non-adherent cells 
were removed and adherent cells were quantified as described in Figure 9. 
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I found that 2F8 specifically inhibited macrophage adhesion while an isotype 
matched control antibody had no effect (Figure 9).   
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Figure  9: RAW264 macrophage were preincubated with 2F8, a monoclonal 
antibody against SR-A, or an isotype matched control antibody (rat IgG2b) for 
15 min. Cells (1.5 x 105 cells/well) were plated in 96-well plates coated with 
collagenase-treated collagen type I. After incubation for one hour, non-
adherent cells were removed. Adherent cells were fixed in paraformaldehyde 
and stained with hematoxylin. Light microscopic pictures of adherent cells 
were captured (10x magnification) with a digital camera and the number of 
adherent cells was determined for one field (10x) per well using ImagePro 
Software. Representative images of untreated control (A) or 2F8 treated (B) 
adherent macrophages. Quantification of adherent cells (C). Data is shown as 
mean ± SEM of six replicates.  
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To verify further that the assay is specific for SR-A, the cells were incubated 
with polyinosine and fucoidan, antagonists of AcLDL binding, before addition 
to the collagen I coated wells. Polyinosine and fucoidan inhibited macrophage 
adhesion, whereas the structural similar compounds polycytidine and 
chondroitin, respectively, had no effect (Figure 10).   
 
 
 
Figure  10:  AcLDL antagonists (Poly(I) and Fucoidan) or structurally similar 
compounds (Poly(C) and Chondroitin), that do not antagonize AcLDL binding 
were preincubated for 15 min with RAW.264 macrophages before the adhesion 
assay was performed as described in Figure 9.  As positive control cells were 
preincubated with 2F8 (3 g/l). A. polyinosine (poly(I)) but not polycytidine 
(poly(C)) inhibited adhesion. B. fucoidan but not chondroitin inhibited 
adhesion.  Data is shown as mean ± SEM of six replicates. 
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To define the region of SR-A that mediated adhesion, I proposed to use fusion 
proteins homologous to SR-A to compete for SR-A mediated cell adhesion 
using this assay. I demonstrated that a fusion protein homologous to the 
extracellular α-helical coiled-coil and collagen-like domains could compete for 
macrophage adhesion (Figure 11).   
crtl '2F8 100 200
n
u
m
be
r 
o
f a
dh
e
re
n
t c
el
ls
0
200
400
600
800
1000
1200
1400
µg/ml SR-A 
extracellular
fusion protein 
 
 
Figure 11:  A fusion protein homologous to the extracellular domain of SR-A 
was incubated with the collagenase-treated collagen type I for 30 min and 2F8 
(3 g/l) was incubated with the RAW264 macrophages for 15 min before the 
adhesion assay was performed as described in Figure 9.  Data is shown as 
mean ± SEM of three replicates.  
 
Overall, I confirmed that the adhesion assay is specific for SR-A mediated 
adhesion. Furthermore, I showed that a fusion protein containing the adhesion 
motif can compete for SR-A mediated adhesion demonstrating the feasibility 
of my approach to define the region containing the adhesion motif. However, 
during the course of the studies other investigators demonstrated that SR-A 
mediated adhesion requires the same domain that mediates binding of 
soluble ligands during internalization (Gowen et al. 2001). Thus, it appeared 
unfeasible to disrupt the adhesive properties without also disrupting ligand 
internalization.  
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3. Cytoplasmic domains mediating for SR-A functions 
 
Previous studies have indicated that SR-A mediated adhesion and 
internalization have common extracellular requirements (Gowen et al. 2001). 
Consequently it has been postulated that SR-A mediated adhesion results 
from an attempt to internalize an immobilized ligand. In contrast, a recent 
study showed that clathrin does not co-localize with SR-A in the filopodia-like 
projections associated with increased adhesion of SR-A expressing cells 
(Post et al. 2002). This finding suggests that SR-A mediated adhesion is a 
process that is independent of clathrin-coated pit mediated endocytosis.  
 
3.1. Expression and post-transcriptional processing 
To investigate the role of the cytoplasmic tail in SR-A-mediated adhesion and 
to determine whether SR-A-mediated adhesion and internalization require 
distinct cytoplasmic domains, I expressed full-length SR-A or different SR-A 
constructs (Table 14) under the control of a tetracycline-inducible promoter in 
HEK 293 cells. 
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Receptor construct Amino acid sequence of amino-terminal cytoplasmic tail 
 
 
 
1                               10                                20                                 30                                 40                                 50             55 
SR-A (full-length) MTKEMTENQRLCPHEREDADCSSESVKFDARSMTASLPHSTKNGPSVQEKLKSFK 
SR-A1-49 MAKLKSFK 
SR-A1-55 MA 
 
 
1                               10                               20                                 30                                  40                                 50                       57 
TfR/SR-A MMDQARSAFSNLFGGEPLSYTRFSLARQVDGDNSHVEMKLAADEEENADNNMKASVR 
 
 
 
Table 14: Amino acid sequences of the amino-terminal cytoplasmic tail of 
SR-A receptor constructs.  Full-length murine SR-A has a 55 amino acid amino-
terminal cytoplasmic tail. SR-A1-49 lacks the first 49 amino acids and SR-A1-55 
lacks all 55 amino acids of the cytoplasmic tail.  TfR/SR-A is a chimeric 
receptor, in which all 55 amino acids of the SR-A cytoplasmic tail are replaced 
by the first 57 amino acids of the murine transferring recptor (TfR). The 
transmembrane and extracellular domains are identical for all receptor 
constructs and correspond to amino acids 56 to 354 of SR-A type II. 
 
I found that deleting the entire 55 amino acid cytoplasmic tail (SR-A1-55) 
greatly diminished SR-A protein abundance compared to that of SR-A full-
length expressing cells (Figure 12A). SR-A protein was not detectable in the 
culture media indicating that the decreased cellular SR-A1-55 protein 
abundance was not due to secretion into the media (data not shown). In 
contrast to complete deletion of the cytoplasmic tail, retaining the membrane-
proximal six amino acids by deleting amino acids 1 to 49 (SR-A1-49) restored 
protein abundance of SR-A (Figure 12A). SR-A mRNA abundance was similar 
for all SR-A constructs (Figure 12B). Thus, my results demonstrate that the 
six membrane-proximal amino acids are required for post-transcriptional 
processing of SR-A.  
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Figure 12: Expression of SR-A constructs in HEK cells. A.  SR-A protein was 
immunoprecipitated from cell lysates (100 g) prepared from uninduced 
(unind) cells or cells induced to express the indicated SR-A construct. 
Precipitated proteins were resolved by SDS-PAGE under reducing conditions 
and SR-A was detected by Western blotting. SR-A protein expression was not 
detectable in lysates prepared from uninduced cells. The blot shown is 
representative of results obtained in two separate experiments. B. RT-PCR was 
performed using primers that amplify a 897 bp fragment spanning the 
transmembrane and extracellular part of SR-A from total RNA (500 ng) isolated 
from induced cells.  PCR products were analyzed by agarose gel 
electrophoresis and visualized by ethidium bromide staining.  SR-A mRNA 
expression was not detectable in uninduced cells. No products were detected 
in control reactions performed without RT or without RNA.  Data shown are 
representative of two separate experiments.  
RESULTS 63
3.2. Cell surface localization and receptor internalization 
To study the role of the membrane-proximal amino acids in SR-A trafficking, I 
analyzed cell surface localization of SR-A1-49. Cell surface localization of SR-
A1-49 was greater than that of full-length SR-A (Figure 13).  
 
SR-A SR-A 1-49
S S ICIC
 
 
Figure 13: Cell surface localization of full-length and SR-A1-49 in HEK cells. 
Cells surface proteins of induced cells were biotinylated and cell lysates were 
prepared. Biotinylated proteins were precipitated from lysates (50 g) using 
streptavidin-coated beads. Total cell surface protein (S, pellet) and 1/10 of the 
intracellular protein (IC, supernatant) were resolved by SDS-PAGE under 
reducing conditions and SR-A was detected by Western blotting. The blot 
shown is representative of three separate experiments. 
 
To address the role of the membrane-proximal amino acids for SR-A 
internalization, I examined internalization of the SR-A ligand AcLDL by 
quantifying cell-associated fluorescence after incubation with fluorescently 
labeled AcLDL for 2 h (Figure 14). As shown previously, HEK-293 cells 
expressing full-length SR-A cells efficiently internalized AcLDL (Post et al. 
2002). However, cell-associated fluorescence detected in cells expressing 
SR-A1-49 was only 14 % of that detected in cells expressing full-length SR-A 
(Figure 14B). The small amount of fluorescence associated with SR-A1-49 
expressing cells most likely reflects AcLDL binding to cell surface receptors. 
The increased cell-associated fluorescence observed in SR-A and SR-A1-49 
expressing cells was completely blocked by the SR-A antagonist polyinosine 
demonstrating specificity. Thus, although SR-A1-49 is able to bind ligand, SR-
A1-49 does not mediate ligand internalization.  
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Figure 14: AcLDL internalization of SR-A and SR-A1-49 expressing HEK 
cells. Cells were induced as indicated. Following incubation in serum-free 
DMEM for 2 h, fluorescently labeled AcLDL (2.5 g/ml, Alexa-Fluor488 AcLDL) 
was added and cells were incubated for another 2 h. AcLDL uptake was 
assessed by quantifying cell-associated fluorescence of uninduced, SR-A 
expressing, and SR-A1-49 expressing cells A.  Histograms of cell-associated 
fluorescence.  Data is representative of two separate experiments. B. 
Quantification of two separate experiments. To determine non-specific AcLDL 
association, polyinosine (10 g/ml) was added before addition of AcLDL. Data 
are the mean fluorescence intensities ± SD of two separate experiments.  
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3.3. Intracellular trafficking from the endoplasmic reticulum to 
the Golgi apparatus 
Previous studies have associated SR-A cell surface localization and receptor 
internalization with a common cytoplasmic motif (Morimoto et al. 1999). 
However, the finding that SR-A1-49 localized to the cell surface, but did not 
internalize ligand, suggests that SR-A trafficking to the cell surface and 
internalization have distinct cytoplasmic requirements. To address the specific 
role of the membrane-proximal amino acids in SR-A trafficking and whether 
an internalization motif is sufficient to mediate cell surface localization, I 
generated a chimeric receptor in which the entire cytoplasmic tail of SR-A was 
replaced by 57 amino acids of the TfR cytoplasmic tail (TfR/SR-A; Table 14) 
omitting a similar membrane-proximal domain. Like SR-A, the TfR is a type II 
transmembrane receptor that mediates internalization via clathrin-coated pits. 
However, whereas the cytoplasmic tail of SR-A is still poorly characterized, 
the cytoplasmic tail of TfR has been studied extensively and contains a well-
characterized internalization motif (YTRF; 15).  
 
To study the trafficking and intracellular processing of the chimeric TfR/SR-A, 
I assessed the ability of TfR/SR-A to form oligomers by resolving cell lysates 
from induced cells under non-reducing conditions. TfR/SR-A was expressed 
and assembled into oligomers similar to SR-A. Monomers of TfR/SR-A and 
SR-A were detected at a molecular weight higher than predicted from the 
amino acid sequences (about 38 kDa) suggesting that both receptors were 
post-translationally modified (Figure 15A). However, the apparent molecular 
weight of TfR/SR-A was lower than SR-A’s indicating that the post-
translational processing was different. 
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Figure 15: Expression and processing of SR-A and TfR/SR-A in HEK cells.   
A. Cell lysates were prepared from induced cells and resolved by SDS-PAGE 
under non-reducing conditions. SR-A and TfR/SR-A were detected by Western 
blotting. Arrows indicate the oligomeric forms of the receptors.  B.  Cells were 
induced for 6 h and cell lysates were prepared.  As indicated, lysates were 
treated with N-glycanase to cleave all N-linked oligosaccarides and were then 
resolved under reducing conditions by SDS-PAGE. SR-A and TfR/SR-A were 
detected by Western blotting.  Each blot is representative of results obtained in 
at least two separate experiments.  
 
To examine the post-translational processing of the SR-A receptor constructs, 
I analyzed N-linked oligosaccharides of the receptors.  An overview of the 
post-translational processing of SR-A’s N-linked oligosaccharides is shown in 
Figure 4. To demonstrate N-linked gycosylation, I digested cell lysates 
prepared from induced cells with N-glycanase (Figure 15B), which cleaves all 
N-linked oligosaccharides. The deglycosylated monomeric proteins were 
detectable at 38 kDa for both SR-A and the chimeric TfR/SR-A indicating that 
the differences in apparent molecular weight resulted from differences in N-
linked oligosaccharides. To test whether the N-linked oligosaccharides of the 
receptors differ in Golgi processing, lysates prepared from induced cells were 
digested with EndoH (Figure 16A). EndoH cleaves the high-mannose 
precursor N-linked oligosaccharides attached in the ER, but not the low-
mannose mature oligosaccharides that are formed after processing in the 
Golgi. In contrast to SR-A (Figure 16A) and SR-A1-49 (data not shown), 
TfR/SR-A (Figure 16A) was EndoH-sensitive indicating that TfR/SR-A was not 
processed into the EndoH-resistant mature form by the Golgi apparatus.   
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Figure 16: A. HEK cells were induced for 6 h and cell lysates prepared.  As 
indicated, lysates were treated with EndoH to cleave only precursor N-linked 
oligosaccharides and were then resolved under reducing conditions by SDS-
Page. SR-A and TfR/SR-A were detected by Western blotting.  B. Cells were 
treated with tunicamycin (5 g/ml) to inhibit formation of N-linked precursor 
oligosaccharides or with brefeldin A (5 g/ml) to prevent maturation of the N-
linked precursor oligosaccarides 60 min before and during induction (6 h). 
Then, cell lysates were prepared and analyzed as in A. Each blot is 
representative of results obtained in at least two separate experiments.  
 
 The EndoH sensitivity of TfR/SR-A suggests that the oligosaccharides of 
TfR/SR-A are analogous to those of the endoH-sensitive SR-A precursor.  To 
confirm this, cells were treated before induction either with brefeldin A, which
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disrupts the Golgi apparatus thereby preventing conversion of the precursor 
into the mature form, or with tunicamycin, an inhibitor of N-linked glycosylation 
(Figure 16B). I found that the apparent molecular weight of the SR-A 
precursor detected in brefeldin A treated cells was the same as that of 
TfR/SR-A in untreated cells. Tunicamycin treatment confirmed the results 
obtained after N-glycanase treatment showing that both receptors were N-
linked glycosylated. Together, the data demonstrate that TfR/SR-A is 
translated and subsequently glycosylated in the ER, but the glycosylated 
precursor is not further processed in the Golgi apparatus. Because TfR/SR-A 
assembles into trimers, it seems unlikely that TfR/SR-A is retained in the ER 
due to misfolding of the protein. As expected, TfR/SR-A was not detected on 
the cell surface using the biotinylation protocol described above (data not 
shown).  
 
Overall, our results from experiments studying the trafficking and intracellular 
processing of the different SR-A constructs demonstrate that an 
internalization motif is not sufficient to mediate trafficking to cell surface. 
Furthermore, the membrane-proximal amino acids of SR-A are sufficient for 
cell surface localization and are specifically required for trafficking of SR-A 
from the ER to the Golgi apparatus. 
 
3.4. Cell spreading and adhesion 
To investigate the cell morphology of cells expressing the SR-A constructs, 
we examined SR-A localization by fluorescence microscopy (Figure 17). 
Consistent with previous findings (Post et al. 2002), SR-A expressing HEK 
cells exhibited a cell morphology characterized by filopodia-like projections 
and increased cell spreading (Figure 17, panels A and B). As expected from 
the lack of surface expression, cells expressing TfR/SR-A (panels C and D) 
exhibited an intracellular immunostaining pattern and no increased cell 
spreading. Interestingly, SR-A1-49 expressing cells (panels E and F) exhibited 
filopodia-like projections and increased cell spreading that was similar to that 
observed for cells expressing full-length SR-A. 
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Figure 17: Cellular morphology of SR-A, TfR/SR-A and SR-A1-49 expressing 
HEK cells.   Cells were plated on glass slides and SR-A (A and B), TfR/SR-A (C 
and D), and SR-A1-49 (E and F) expression was induced. After the induced cells 
were fixed and permeabilized, SR-A construct expression was detected using 
2F8 and a secondary Alexa-Fluor488 labeled anti-rat antibody (A, C, E).  No 
fluorescence was detectable in uninduced cells (not shown). The nuclei were 
stained with DAPI (B, D, F). 
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As the presence of the filopodia-like projections and increased cell spreading 
are associated with increased cell adhesion of SR-A expressing cells, we 
analyzed cell adhesion of cells expressing the different SR-A constructs. 
Consistent with increased spreading of SR-A and SR-A1-49 expressing cells, 
both receptors were able to increase cell adhesion to the same extent (Figure 
18), demonstrating that the membrane-proximal amino acids are sufficient for 
SR-A-mediated adhesion. As expected from the lack of surface expression, 
TfR/SR-A (Figure 18) did not  increase cell adhesion.  
 
 
Figure 18: Divalent-cation independent cell adhesion of HEK cells. Cells 
were plated in 96-well plates (20,000 cells/well) and induced as indicated. Then, 
cells were incubated in EDTA solution (0.2 g/ml) for 10 min to eliminate 
divalent-cation dependent adhesion. Cell that remained adhered were 
quantified by CyQUANT assay.  Adhesion is expressed as percent of total cells 
plated. Data shown is representative of two separate experiments.  
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V Discussion 
1. SR-A transgenic mice 
 
I have characterized functional changes in peritoneal macrophages isolated 
from lyso-bSR-A transgenic mice, which express SR-A in a macrophage-
specific manner.  Expression of bSR-A mRNA had been confirmed by RT-
PCR.  Because there is no antibody available that specifically recognizes 
bSR-A, the protein expression of the bSR-A transgene cannot be determined 
specifically.  However, I did confirm bSR-A protein expression by 
characterizing functional changes.  I found that bSR-A expression enhanced 
ligand internalization and cell spreading of peritoneal macrophages from lyso-
bSR-A transgenic mice.  Therefore, my results demonstrate that lyso-bSR-A 
transgenic mice express the transgene and exhibit enhanced macrophage 
SR-A activity in vitro. 
 
Mouse models are powerful tools to study the role of specific genes in vivo. 
Mice are genetically well characterized and genetic manipulations allow 
deletion or overexpression of genes. The effect of deleting or overexpressing 
a gene can then be studied in different disease models. Initial studies in SR-A 
deficient mice have demonstrated the importance of SR-A in host defense and 
atherosclerosis (Suzuki et al. 1997). Whereas at this time it is well established 
that SR-A has a protective role in host defense, the role of SR-A in 
atherogenesis is still controversial.  
 
Although mice had been considered to be resistant against atherosclerosis, in 
1985 it was described that several inbred mouse strain develop diet-induced 
atherosclerosis, when fed a non-physiological diet containing high 
concentrations of saturated fat (21%), cholesterol (1.25%) and cholate (0.5%) 
(Paigen et al. 1985).  The most susceptible mouse strain was the C57BL/6, 
and since then the C57BL/6 became the most widely used inbred strain to 
study atherosclerosis.  
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Atherosclerotic lesions of C57BL/6 mice are comparable to early stage lesions 
in humans; however, the lesions are small and restricted to the aortic root 
making analysis difficult. To enhance lesion development in C57BL/6 mice, 
genetic manipulations that interfere with the lipoprotein metabolism have been 
introduced. Deletion of apoE (Zhang et al. 1992; Plump et al. 1992), which is 
necessary for the clearance of cholesterol-rich lipoproteins, and deletion of the 
LDL receptor (LDL-R) (Ishibashi et al. 1994), which mediates cellular uptake 
of lipoproteins, cause hypercholesterolemia and enhance atherosclerotic 
lesion development. The lesions of apoE and LDL-R deficient C57BL/6 mice 
are more advanced than those in wild-type C57BL/6 mice and resemble 
several stages of human lesions. Furthermore, lesion development is not 
restricted to the aortic root; lesions develop throughout the aortic tree 
facilitating analysis of lesion development. Therefore, apoE and LDL-R 
deficient C57BL/6 mice are the most commonly used mouse models of 
atherosclerosis.  
 
SR-A deficiency and overexpression have been studied in several mouse 
models of atherosclerosis including wild-type and apoE or LDL-R deficient 
C57BL/6 (Table 4). However, the results are inconsistent: initial studies 
demonstrated a proatherogenic role of SR-A, but consequent studies also 
have demonstrated no effect or antiatherogenic effects. One reason for the 
inconsistent results might be that SR-A is expressed on several cell types and 
the contribution of SR-A on the various cell types might vary in different 
models.   
 
The use of a cell-specific promoter in lyso-bSR-A transgenic mice made it 
possible to address specifically macrophage SR-A overexpression. Studies in 
our laboratory using the lyso-bSR-A transgenic mice demonstated an 
antiatherogenic effect of macrophage-specific overexpression of SR-A after 
bone marrow transfer into LDL-R mice (Whitman et al. 2002).  However, 
another group of investigators addressed macrophage specific deficiency of 
SR-A and demonstrated a proatherogenic effect. (Babaev et al. 2000). Thus, 
even the results from studies addressing the role of macrophage specific SR-
A expression are inconsistent. 
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Another reason for the inconsistent results of studies addressing the role of 
SR-A in atherosclerosis might be that the contribution of the different functions 
mediated by SR-A such as lipoprotein internalization and adhesion might vary. 
However, to date it has not been possible to specifically address the relative 
contributions of SR-A mediated lipoprotein internalization and adhesion.    
 
2. SR-A mediated lipoprotein internalization 
I have shown that overexpression of SR-A enhanced internalization of AcLDL 
in peritoneal macrophages isolated from lyso-bSR-A transgenic mice. It is well 
established that SR-A mediated internalization of modified lipoproteins can 
result in cholesterol ester accumulation and thus foam cell formation in vitro 
(Brown et al. 1979).   
 
The role of SR-A mediated internalization during foam cell formation in vitro 
has been confirmed in SR-A deficient mice.  In vitro studies in peritoneal 
macrophages isolated from SR-A deficient mice showed that SR-A deficiency 
decreases AcLDL degradation by 80 % and OxLDL degradation by 30 % 
(Suzuki et al. 1997). In vivo, SR-A deficiency decreased atherosclerotic lesion 
development. However, SR-A deficient mice develop atherosclerotic lesions 
rich in foam cells (Suzuki et al. 1997). Taken together, these findings support 
the notion that SR-A is involved in foam cells formation during atherosclerosis, 
but demonstrate that other scavenger receptors are also involved. 
 
Although SR-A was the first scavenger receptor that was identified and 
consequently thought to mediate foam cell formation during atherogenesis, by 
now several other scavenger receptors, defined by their ability to recognize 
modified lipoproteins, have been described. Several of the other scavenger 
receptors have been detected in addition to SR-A in atherosclerotic lesions 
and thus suggested to be involved in uptake of modified lipoproteins during
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atherogenesis. These receptors include: CD36 (Endemann et al. 1993), 
macrosialin/CD68 (Ramprasad et al. 1996), lectin-like oxidized LDL receptor 
(LOX-1) (Sawamura et al. 1997) scavenger receptor for phosphotidylserine 
and oxidized lipoproteins (SR-PSOX) (Shimaoka et al. 2000; Minami et al. 
2001). However, the contribution of these receptors to foam cell formation and 
atherosclerotic lesion development remains controversial.  The redundancy of 
the system makes it difficult to address the role of individual receptors.  Mice 
genetically deficient in individual receptors are a powerful tool to elucidate the 
role of individual receptors, but a potential problem is that compensatory 
mechanisms might develop and confound the results.   
 
One of the scavenger receptors considered to potentially play a role during 
atherosclerois is macrosialin, the mouse homolog of human CD68. 
Macrosialin had been suggested as receptor for oxLDL on the basis of ligand 
blotting studies (Ramprasad et al. 1996), and macrosialin is expressed in 
atherosclerotic lesions (de Villiers et al. 1998). However, it has been recently 
shown that oxLDL does not bind to macrosialin expressed on the cell surface 
of transfected COS-7 cells demonstrating that macrosialin does not play a role 
in metablolism of oxLDL (De Beer et al. 2003). 
 
Another scavenger receptor that has been detected in atherosclerotic lesions 
is CD36. The important role of CD36 in atherogenesis has been confirmed in 
CD36 deficient mice on an ApoE deficient background (Febbraio et al. 2000).  
In vitro studies in peritoneal macrophages isolated from these mice showed 
that CD36 deficiency decreased OxLDL degradation by more than 60 %. In 
vivo, CD36 deficiency decreased lesion development by 77 % (in the aortic 
tree) when fed a Western diet and by 45% (in aortic sinus) when fed a normal 
diet. Similar to the finding in SR-A deficient mice, CD36 deficiency did not 
prevent foam cell formation. Studies in mice deficient in SR-A and CD36 will 
be necessary to define whether other scavenger receptors in addition to SR-A 
and CD36 play a role during atherogensis.  
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Recently, mice that are deficient in SR-A and CD36 were described 
(Kunjathoor et al. 2002). Althought atherosclerotic lesion development in 
these mice has not been characterized, in vitro studies addressed the role of 
these receptors during foam cell formation.  Peritoneal macrophages isolated 
from these double deficient mice degraded 75 -90 % less modified 
lipoproteins (including AcLDL, mildly and extensively oxLDL and 
myeloperoxidase modified LDL).  Peritoneal macrophages isolated from the 
double deficient mice did not accumulate cholesterol esters in response to 
modified lipoproteins demonstrating that SR-A and CD36 are the main 
receptors mediating macrophage foam cell formation in vitro.  As 
macrophages from these SR-A and CD36 mice deficient mice are protected 
from foam cell formation in vitro, it will be interesting to see whether these 
mice are protected from atherosclerosic lesion development.  
 
Although SR-A promotes cholesterol accumulation in vitro, it remains 
controversial whether SR-A promotes foam cell formation in vivo. The 
accumulation of cholesterol esters induced by SR-A mediated lipoprotein 
internalization is reversible (Brown et al. 1979). In vivo, cholesterol acceptors 
are present and they might allow cholesterol efflux from the macrophages 
thus preventing foam cell formation. Therefore, internalization of modified 
lipoproteins via SR-A does not necessary lead to foam cell formation.  
 
Furthermore, it is unclear to which extent SR-A is involved in internalization of 
modified lipoproteins in vivo. Although SR-A deficiency decreases degradation 
of modified lipoproteins by macrophages in vitro, it has been shown that 
modified lipoproteins can be rapidly metabolized in SR-A deficient mice (Ling 
et al. 1997; Van Berkel et al. 1998). There is evidence supporting that SR-A 
might predominantly function as adhesion molecule in vivo. Studies using the 
lyso-bSR-A mice found that overexpression of SR-A enhanced granuloma 
formation by increasing macrophage retention, while it did not increase 
intracellular lipid accumulation (Daugherty et al. 2001). It also has been shown 
that SR-A mediated internalization of AcLDL is abolished if macrophages
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 adhere via SR-A (el Khoury et al. 1994). Therefore, it is possible that in vivo 
SR-A functions as adhesion molecule to increase macrophage retention while 
other scavenger receptors mediate uptake of modified lipoprotein. 
 
3. SR-A mediated adhesion 
I found that overexpression of SR-A in lyso-bSR-A transgenic mice enhanced 
macrophage spreading in addition to increased internalization of lipoproteins. 
The finding that macrophages from SR-A transgenic mice exhibit increased 
spreading in culture demonstrates the adhesive properties of SR-A.  Our 
finding is consistent with the observation that SR-A deficient macrophages 
exhibit slowed spreading (Suzuki et al. 1997).  Furthermore, HEK cells, which 
do not express SR-A and are usually weakly adherent, exhibit a more 
adherent phenotype upon transfection with SR-A (Robbins et al. 1998; Post et 
al. 2002).  Although the adhesive properties of SR-A are established in vitro, 
the role of SR-A mediated adhesion in vivo is not known. 
 
SR-A-mediated adhesion may have important physiological roles by 
increasing the retention of macrophages.  Macrophages are important 
mediators of inflammatory processes by releasing inflammatory mediators, 
growth factors and matrix degrading enzymes.  SR-A is expressed strongly on 
macrophages at sites of tissue injury associated with inflammatory processes 
such as atheroscleroic lesions and senile plaques of Alzheimer's disease.  
While in resident macrophages adhesion is mainly mediated by integrins 
(Albelda et al. 1990), upon activation of macrophages SR-A mediated 
adhesion is upregulated (van Velzen et al. 1999).  In vivo studies using the 
lyso-bSR-A transgenic mice demonstrated a role of SR-A-mediated adhesion 
in a model of inflammation (Daugherty et al. 2001). The macrophage-specific 
overexpression of SR-A in lyso-bSR-A mice enhanced granuloma formation 
after subcutaneous injection of carrageenan.  This enhanced granuloma
DISCUSSION 77 
 formation was associated with an increase in macrophage numbers 
suggesting that SR-A enhanced macrophage recruitment and/or retention. 
Thus, SR-A mediated adhesion might be a mechanism for increasing 
macrophage retention specifically at sites of tissue inflammation. 
 
Further support for the hypothesis that SR-A may be involved in macrophage 
retention at sites of tissue inflammation is provided by the identification of 
adhesion substrates that are associated with sites of inflammation. SR-A 
mediates adhesion specifically to modified extracellular matrix proteins such 
as collagen type I, III, and IV (el Khoury et al. 1994; Gowen et al. 2000). 
These modifications of the extracellular matrix included denaturation and 
glycation and may occur during certain pathophysiological conditions such as 
hyperglycemia or inflammation. Recently, SR-A also has been shown to 
mediate adhesion to proteoglycans of the extracellular matrix that are present 
in atherosclerotic lesions (Santiago-Garcia et al. 2003). Furthermore, SR-A 
mediates adhesion of microglial cells to beta-amyloid fibrils which accumulate 
in plaques of Alzheimer's disease (El Khoury et al. 1996). Thus, SR-A might 
increase macrophage retention at sites of inflammation through adhesion to 
modified extracellular matrix proteins.  
 
4. Extracellular requirements for SR-A mediated adhesion 
Despite the evidence supporting an important role of SR-A mediated 
adhesion, the relative contribution of SR-A mediated adhesion in vivo is 
unknown, as it has not been possible to block SR-A mediated adhesion 
specifically. To be able to address the role of SR-A mediated adhesion 
specifically, my aim was to identify the motif in the extracellular domains of 
SR-A that mediates adhesion. If a specific adhesion motif is defined, this motif 
can be mutated by site-directed mutagenesis to disrupt the adhesion 
properties of SR-A specifically. Expression of a SR-A mutant specifically 
lacking the adhesion properties in SR-A deficient mice will allow defining the 
role of SR-A's adhesion properties in vivo.  
DISCUSSION 78 
 
To identify the adhesion motif, I modified a SR-A dependent adhesion assay 
described previously by Gowen et al. (Gowen et al. 2000). Gowen et al. 
demonstrated that adhesion of RAW.264 macrophages to collagenase-
digested collagen type I is mediated by SR-A. I chose this assay as 
collagenase-digested collagen type I might be a substrate for SR-A mediated 
adhesion during atherosclerosis in vivo. Collagen type I is a major 
extracellular matrix protein within the arterial wall and its synthesis is 
increased in atherosclerotic lesions (Rekhter et al. 1993).  Moreover, during 
atherogenesis several matrix-degrading enzymes that have collagenase 
activity are present in the lesion (Galis et al. 1994). 
 
It has been shown that SR-A mediated adhesion can be blocked by the 
monoclonal SR-A antibody, 2F8, and by antagonists of AcLDL binding (Fraser 
et al. 1993; el Khoury et al. 1994; Gowen et al. 2000). Therefore, the 
macrophages were preincubated with 2F8 or the antagonists polyinosine and 
fucoidan to confirm the specificity of the assay. Unlike integrin-mediated 
adhesion, SR-A mediated adhesion does not depend on divalent cations; 
therefore, the adhesion assay was performed in the absence of divalent 
cations to exclude integrin-mediated adhesion. I found that 2F8 blocked SR-A 
mediated macrophage adhesion, whereas an isotype matched control 
antibody had no effect (Figure 9). Furthermore, I found that polyinosine and 
fucoidan, also inhibited macrophage adhesion, whereas the structural similar 
compounds polycytidine and chondroitin, respectively, had no effect (Figure 
10). Thus, these results demonstrate that under the conditions of the assay 
macrophage adhesion is mainly mediated by SR-A.  
 
Although studies using monoclonal antibodies and SR-A ligands are suitable 
to address whether adhesion is mediated by SR-A, due to the conformation of 
SR-A such studies cannot be used to define the location of the adhesion 
motif. The conformation of SR-A was shown to resemble a hairpin, in which
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 the α-helical coiled coil and collagen-like domains are juxtapositional (Figure 
3) (Resnick et al. 1996). Therefore, binding of antibodies or ligands to one 
domain can mask binding sites in the other domain through steric hindrance. 
For example, although the binding epitope for 2F8 is located in the N-terminal 
region of the α-helical coiled coil (Daugherty et al. 2000), 2F8 is able to 
antagonize AcLDL binding, which occurs at the C-terminal end of the 
collagen-like domain. Similarly, the adhesion motif might be masked through 
steric hindrance. Consequently, another approach is necessary to define the 
adhesion motif.  
 
To define the adhesion motif, I proposed to compete for SR-A mediated 
macrophage adhesion with peptides homologous to SR-A. Peptides 
containing the adhesion motif will compete for SR-A binding sites of the 
adhesion matrix and therefore block SR-A mediated macrophage adhesion. It 
has been previously demonstrated that preincubation of modified collagen 
type IV with a peptide homologous to part of the collagen-like domain of SR-A 
could decrease SR-A mediated adhesion (el Khoury et al. 1994). Unlike 
observed for inhibition of AcLDL binding with peptides (Yamamoto et al. 
1997), which required trimeric peptides, monomeric peptides were sufficient to 
inhibit adhesion. Therefore, I proposed to use fusion proteins to compete for 
SR-A mediated adhesion. To confirm that these monomeric fusion proteins 
are able to inhibit macrophage adhesion, I preincubated the digested collagen 
type I with a fusion protein homologous to the α-helical coiled coil and the 
collagen-like domains. These domains are common to SR-A type I and II, 
which are both able to mediate adhesion and thus, the adhesion motif must be 
located within these domains. I found that that this fusion protein could block 
SR-A mediated macrophage adhesion (Figure 11). Therefore, I verified that 
fusion proteins containing the adhesion motif can compete for SR-A binding. 
By analyzing the inhibitory properties of fusion proteins that are sequentially 
truncated, the region that contains the adhesion motif could have been 
narrowed down. Finally, site directed mutants of this region could have been 
used to define the adhesion motif.  
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However, during the course of these studies, structure-function studies by 
other investigators have also addressed the localization of the adhesion motif. 
While transient expression of full-length SR-A type II of COS cells conferred 
adhesion to collagen type I, expression of a truncated receptor lacking the 
distal portion of the collagenous domain did not (Gowen et al. 2001). 
Furthermore, a peptide homologous to 10 amino acids of the collagen-like 
domain containing the residues critical for ligand binding could block 
macrophage adhesion (Gowen et al. 2001). Taken together, the data strongly 
support that SR-A-mediated adhesion depends on the same region in the 
collagen-like domain of SR-A that mediates binding of soluble ligands during 
internalization. Thus, it does not appear to be feasible to generate a SR-A 
receptor mutant specifically lacking the adhesion properties, without disrupting 
binding of soluble ligands.   
 
Due to the inability to separate SR-A-mediated adhesion from ligand 
internalization using 2F8 and SR-A ligands as described above (Fraser et al. 
1993; el Khoury et al. 1994; Gowen et al. 2000; Gowen et al. 2001), it has 
been hypothesized that SR-A-mediated adhesion results from the attempt to 
internalize an immobilized ligand (Fong et al. 1999). The finding that SR-A 
mediated adhesion and internalization of soluble ligands depend on the same 
region of the extracellular domain supports this hypothesis. In contrast to data 
supporting a common mechanism for adhesion and internalization, recent 
studies showed that clathrin does not co-localize with SR-A in the filopodia-
like projections associated with the enhanced adhesion of SR-A expressing 
cells (Post et al. 2002). This observation provided indirect evidence that SR-A-
mediated adhesion is a process that is distinct from clathrin-coated pit 
internalization. 
5. The role of cytoplasmic domains in SR-A function 
As it appeared to be unfeasible to generate a mutant of SR-A specifically 
lacking the adhesion properties by modifying the extracellular domains, I 
wanted to investigate the role of the cytoplasmic tail in SR-A-mediated 
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adhesion. In particular, I wanted to address whether SR-A-mediated adhesion 
and internalization require distinct cytoplasmic domains. To address this 
question, I expressed different SR-A constructs under the control of an 
inducible promoter in stably transfected HEK-293 cells.  
 
HEK-293 cells do not express endogenous SR-A and are a weakly adherent 
cell line. It has been shown that HEK-293 exhibit a more adherent phenotype 
upon transfection with SR-A (Robbins et al. 1998). Therefore, use of this cell 
line provides a good model to address the adhesive properties of expressed 
SR-A receptor constructs. Furthermore, transfected HEK-293 cells have been 
used to study SR-A mediated internalization of modified lipoproteins (Lysko et 
al. 1999; Post et al. 2002). It was also shown that SR-A mediated 
internalization is similarly regulated in HEK-293 cells expressing SR-A and 
mouse peritoneal macrophages (Post et al. 2002). Therefore, this cell line also 
provides a good model to address SR-A mediated internalization. To generate 
HEK-293 cells that express the different SR-A constructs, we used the Flp-
InTM T-RExTM system (Invitrogen). This system allows tetracycline-inducible 
expression after integration of the cDNA into a single specific genomic site. An 
important advantage of this system is that similar levels of expression can be 
obtained upon induction of cells transfected with different cDNAs. Taken 
together, HEK-293 cells expressing the different SR-A constructs using the 
Flp-InTM T-RExTM system provide a good model to compare the adhesive and 
internalization properties of the different SR-A constructs.   
 
I found that complete truncation of the cytoplasmic tail (SR-A1-55) dramatically 
decreased the protein abundance of SR-A compared to that of cells 
expressing full-length SR-A. This finding demonstrates that the cytoplasmic 
tail is critical for the processing of SR-A. As we have shown that the mRNA 
abundance of the receptor constructs is similar upon induction, the decreased 
protein abundance was not due to differences in mRNA transcription, but due 
to differences in post-transcriptional processing. 
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An initial step in the post-transcriptional processing of SR-A is insertion of the 
nascent protein into the membrane of the ER. The process whereby 
transmembrane proteins are inserted into the ER membrane and adopt a type 
I (carboxy-terminal cytoplasmic tail) or type II (amino-terminal cytoplasmic tail) 
topology is not fully understood (Wilkinson et al. 1997).  It is generally thought 
that type I and II transmembrane proteins are targeted to the ER and then 
inserted and anchored in the membrane via a process involving signal-anchor 
sequences located in the hydrophobic amino acids of the transmembrane 
domains. However, I found that the transmembrane domain of SR-A (SR-A1-
55) was not sufficient for the post-transcriptional processing of SR-A.  
 
In contrast to the dramatically decreased protein abundance of SR-A after 
complete truncation of the cytoplasmic tail (SR-A1-55), retaining the 
membrane-proximal amino acids of the cytoplasmic tail (SR-A1-49) restored 
SR-A protein abundance. Three of the six retained SR-A membrane-proximal 
amino acids (KLKSFK) are positively charged. Charged membrane-proximal 
amino acids have been shown to affect the topology of transmembrane 
proteins (Spiess 1995).  Thus, the membrane-proximal charged residues 
might be critical during ER membrane insertion of SR-A. 
 
Binding of a number of cytosolic proteins is involved in processing of newly 
synthesized proteins and membrane translocation. As the cytoplasmic tail is 
the N-terminal end of SR-A, this part is synthesized first and it might be critical 
for binding of proteins during early processing.  One group of cytosolic 
proteins that many newly synthesized proteins interact transiently with is 
chaperones (Beckmann et al. 1990).  For example, binding of the chaperone 
heat shock protein (Hsp) 70 is required during apolipoprotein B synthesis and 
ER translocation (Zhou et al. 1995). Binding of Hsp70 and Hsp90 has also 
beenshown to mediate translocation across the mitochondrial membrane (Ellis 
2003).  It has been shown that the Hsp70 and Hsp90 directly bind to the 
cytoplasmic tail of SR-A (Nakamura et al. 2002). Thus, the membrane-
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proximal amino acids might provide a recognition site for proteins critical 
during membrane insertion.  
 
To address the specific requirement for the membrane-proximal amino acids, I 
replaced the cytoplasmic tail of SR-A with the first 57 amino acids of the 
transferrin receptor (TfR) omitting the TfR charged membrane-proximal amino 
acids (KPKR). I chose the TfR for a number of reasons. Like SR-A, TfR is a 
type II transmembrane protein that mediates clathrin-coated pit endocytosis. 
In contrast to SR-A, endocytosis is the only function mediated by TfR. The 
cytoplasmic motif (YTRF) of the TfR required for internalization is well-defined 
and mutation of this motif dramatically reduces TfR internalization (Jing et al. 
1990). If the chimeric TfR/SR-A had been expressed on the cell surface, 
TfR/SR-A could have been used to specifically address the role of 
internalization of SR-A ligands. TfR/SR-A should be able to mediate ligand 
internalization via the YTRF internalization motif of the TfR. Moreover, after 
mutation of the internalization motif TfR/SR-A could have been used to 
address the role of SR-A cell surface localization. Comparison of the adhesive 
properties of cells expressing the internalization deficient TfR/SR-A and 
SR-A1-49 could have addressed whether cell surface localization alone is 
sufficient for SR-A mediated adhesion or whether the membrane-proximal 
amino acids of SR-A are specifically required for SR-A mediated adhesion. 
 
However, although TfR/SR-A expression was detectable in whole cell lysates, 
TfR/SR-A was not detectable on the cell surface. We analyzed the 
intracellular processing and found, that the chimeric TfR/SR-A receptor was 
glycosylated in the ER, but not processed in the Golgi apparatus indicating 
that the receptor was not transported from the ER to the Golgi. The 
glycosylated TfR/SR-A monomer is similar to the glycosylated full-length SR-A 
monomer formed in the ER. Because TfR/SR-A assembles into trimers, it 
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seems unlikely that TfR/SR-A is retained in the ER due to misfolding. I 
conclude that the membrane-proximal amino acids are specifically required for 
trafficking from ER to the Golgi.  
  
The mechanism by which proteins traffic from the ER to Golgi remains 
controversial (Klumperman 2000). The bulk-flow model proposes that proteins 
are transported from the ER to the Golgi by default. In contrast, the selective 
export model proposes that proteins are selectively exported based on the 
presence of ER-export signals (Gorelick et al. 2001). Several cytosolic 
proteins are involved in trafficking of newly synthesized transmembrane 
proteins. Thus, the membrane-proximal amino acids might provide a critical 
recognition site for proteins involved in selective ER export. 
 
In addition to being required for trafficking from the ER to the Golgi, the 
membrane-proximal amino acids were sufficient for cell surface localization of 
the receptor. Although SR-A1-49 was expressed primarily on the cell surface, 
SR-A1-49 failed to internalize ligand. The lack of SR-A1-49 internalization may 
cause the increased cell surface localization of SR-A1-49 (Figure 13). A well-
defined internalization motif is not present in the cytoplasmic tail of SR-A.  
However, Morimoto et al. have suggested that a single motif, VXFD, is 
required for both SR-A internalization and cell surface localization (Morimoto 
et al. 1999).  In contrast, my results show that the membrane-proximal amino 
acids are sufficient for cell surface localization, but that receptor internalization 
depends on a distinct motif, possibly the VXFD motif.  
 
Although SRA1-49 did not mediate ligand internalization, the receptor 
mediated cell adhesion. The mechanism by which SR-A mediates cell 
adhesion remains unclear. It has been shown, that SR-A-mediated adhesion 
involves changes in the actin cytoskeleton and the formation of focal 
adhesions.  The ability of SRA1-49 to enhance cell adhesion suggests that the 
membrane-proximal amino acids of SR-A are sufficient to mediate these 
processes. Likewise, the cytoplasmic membrane-proximal amino acids of the
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 adhesion molecule L1 have been shown to be sufficient for association of this 
receptor with the cytoskeleton (Dahlin-Huppe et al. 1997). Thus, the 
membrane-proximal amino acids of SR-A might be a binding site for cytosolic 
proteins involved in formation of focal adhesions. However, cell surface 
localization might be sufficient to mediate cell adhesion. For example the uPA 
receptor, a GPI anchored protein, has been shown to mediate cell adhesion 
through association with integrins (Wei et al. 1996). Similarly, SR-A might 
associate though its extracellular domains with another receptor to mediate 
adhesion.  
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VI Conclusions and Future Directions 
 
SR-A overexpression enhances lipoprotein internalization and adhesive 
properties of macrophages in vitro. Both functions might play an important 
physiological role, but their relative contribution in vivo is unknown. It 
appeared that these two functions depend on the same extracellular region of 
SR-A. Thus, to dissect SR-A mediated cell adhesion and lipoprotein 
internalization, I investigated the role of cytoplasmic domains for SR-A 
function. I found that the cytoplasmic tail plays a critical role in SR-A 
processing and trafficking. Furthermore, I identified a mutant of SR-A that 
specifically mediates cell adhesion, but not ligand internalization. This finding 
demonstrates that SR-A mediated adhesion and internalization require distinct 
cytoplasmic domains and therefore must be distinct cellular processes.  
 
The development of the SRA1-49 mutant that specifically mediates cell 
adhesion will make it possible to study SR-A-mediated adhesion. Cell culture 
studies can elucidate the mechanism by which the adhesion is regulated. 
Expression of SRA1-49  in a SR-A deficient mouse model can address the 
contribution of SR-A mediated adhesion in various physiological and 
pathophysiologial processes such as atherosclerosis. 
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VII Summary 
Class A scavenger receptors (SR-A) are trimeric transmembrane 
glycoproteins that are mainly expressed in macrophages. SR-A can bind a 
variety of ligands including modified lipoproteins and bacterial products. 
Through its ability to internalize these ligands, SR-A is thought to be involved 
in many physiological and pathophysiological processes such as host defense 
and atherosclerosis. In vitro, SR-A also mediates cell adhesion to modified 
extracellular matrix proteins. Thus, SR-A mediated adhesion may play an 
important physiological role by increasing the retention of macrophages. 
However, to date it has not been possible to define specifically the 
physiological role of SR-A mediated cell adhesion. 
The goal of my thesis project was to dissect SR-A mediated cell 
adhesion and ligand internalization and to develop a mutant of SR-A that 
specifically lacks the adhesive properties.  
In initial studies I characterized peritoneal macrophages from 
transgenic mice that overexpress SR-A in macrophages. SR-A 
overexpression augmented cholesterol ester deposition of peritoneal 
macrophages in response to AcLDL indicating increased internalization of 
AcLDL. Furthermore, these cells exhibited enhanced cell spreading. This 
finding suggested that overexpression of SR-A can increase macrophage 
adhesion.  
To develop a mutant of SR-A lacking the adhesion properties, I 
performed studies to define the adhesion motif in the extracellular domain of 
SR-A in order to determine if the extracellular motif involved in adhesion can 
be distinguished from the motif involved in ligand binding during 
internalization. I studied SR-A mediated adhesion of RAW.264 macrophages 
to denatured collagen type I. SR-A mediated adhesion was inhibited by the rat 
SR-A monoclonal antibody 2F8 and by the SR-A antagonists polyinosine and 
fucoidan. Furthermore, a fusion protein homologous to the extracellular 
domain of SR-A competed for cell adhesion. My approach was to define the 
adhesion motif by testing the ability of shorter fusion proteins to compete for 
cell adhesion. However, using this approach it was not 
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possible to define an extracellular adhesion motif that is distinct from the 
lipoprotein binding domain, as it appeared that ligand binding during receptor 
internalization and adhesion depend on the same extracellular domain.  
 Because the cytoplasmic tail is required for receptor internalization, I 
investigated the role of cytoplasmic domains for SR-A mediated functions.  
Different cytoplasmic mutated SR-A constructs were stably expressed in 
human embryonic kidney (HEK 293) cells. Complete deletion of the 
cytoplasmic tail (SRA1-55) greatly diminished SR-A protein expression. 
However, a mutated SR-A deficient in all but the six amino acids proximal to 
the membrane of the cytoplasmic tail (SRA1-49) was expressed and localized 
to the cell surface. Substitution of the SR-A cytoplasmic tail with that of the 
transferrin receptor (TfR/SR-A) resulted in retention of this chimeric receptor 
in the endoplasmic reticulum demonstrating that the SR-A membrane 
proximal amino acids are critical for trafficking of the receptor from the 
endoplasmic reticulum to the Golgi apparatus. Furthermore, these membrane 
proximal amino acids were sufficient for SR-A mediated cell adhesion, but not 
for receptor internalization.  
 My results demonstrate that the cytoplasmic tail plays a critical role for 
SR-A processing and trafficking. Furthermore, SR-A-mediated adhesion and 
internalization require distinct cytoplasmic domains and therefore must be 
distinct cellular processes. The identification of a SR-A mutant that specifically 
meditates cell adhesion, such as SRA1-49, will make it possible to specifically 
address the physiological role of SR-A mediated adhesion.
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